MEMORANDUM

TO: RTOG Clinical Research Associates and Investigators
Operations Offices of SWOG, NCCTG

FROM: RTOG Protocol Development Department

DATE: October 4, 2002

SUBJECT: Terminated Protocols: RTOG Coordinated Studies No Longer Requiring Routine Data Submission

Effective October 18, 2002, you are no longer required to submit follow-up information for the protocols on this list. Further management of the patients on these trials will be left to the discretion of the treating physician. After October 18, 2002, data submitted to the RTOG for the protocols on this list will be returned to you. Exception: the NCI AML/MDS form should be completed and submitted for any cases diagnosed with AML/MDS.

There remain many older studies that are not on this list. We will continue with the current follow-up and data submission schedule on these studies. They will be reviewed annually to determine when follow-up may be terminated.

<table>
<thead>
<tr>
<th>RTOG Protocol Number</th>
<th>Protocol Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>8501</td>
<td>Phase III Prospective Trial for Localized Cancer of the Esophagus: Comparing Radiation as a Single Modality to the Combination of Radiation Therapy and Chemotherapy (Participants: SWOG, NCCTG)</td>
</tr>
<tr>
<td>8902</td>
<td>Phase I/II Study of Sphincter Sparing Local Excision Combined with Post-operative Radiation Therapy and Concurrent 5-FU in the Treatment of Limited Adenocarcinoma of the Rectum</td>
</tr>
<tr>
<td>9006</td>
<td>A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) with BCNU and Conventional RT with BCNU for Supratentorial Malignant Glioma</td>
</tr>
<tr>
<td>9103</td>
<td>Pulmonary Function of Patients with Radiation Therapy for Non-Small Lung Cancer</td>
</tr>
<tr>
<td>9204</td>
<td>Randomized Phase II Study of Chemotherapy/Radiation Therapy Combinations for Favorable Patients with Locally Advanced Inoperable Non-Small Cell Lung Cancer (NSCLC)</td>
</tr>
<tr>
<td>9207</td>
<td>A Phase I/II Trial for Localized Cancer of the Esophagus: External Beam Irradiation, Esophageal Brachytherapy and Combination Chemotherapy</td>
</tr>
<tr>
<td>9210</td>
<td>A Phase II Study of a Twice Daily Fractionation Schedule with External Irradiation and Intracavitary Brachytherapy and Chemotherapy (CDDP, 5-FU) in Carcinoma of the Cervix with Positive Para-Aortic Lymph Nodes</td>
</tr>
<tr>
<td>9304</td>
<td>Phase III Conventional Therapy with or without Recombinant ß-Interferon for Patients with Locally Advanced Non-Small Cell Lung Cancer</td>
</tr>
<tr>
<td>9312</td>
<td>Phase II Study of Cisplatin, Ifosfamide/Mesna, Etoposide, and Concurrent Accelerated Hyperfractionated Thoracic Radiotherapy for Patients with Limited Small Cell Lung Cancer</td>
</tr>
<tr>
<td>RTOG Protocol Number</td>
<td>Protocol Title</td>
</tr>
<tr>
<td>----------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>9404</td>
<td>A Phase III Randomized Study of Radiotherapy with or without BUdR Plus Procarbazine, CCNU, and Vincristine (PCV) for the Treatment of Anaplastic Astrocytomas (Participants: SWOG, NCCTG)</td>
</tr>
<tr>
<td>9417</td>
<td>A Single-Arm, Open-Label, Phase II Study of Intravenously Administered Tirapazamine plus Radiation Therapy for High Grade Glioblastoma Multiforme</td>
</tr>
<tr>
<td>9502</td>
<td>Phase IB Study of Radiosurgery and Elnidazole (SR-2508) for the Treatment of Recurrent Primary Brain Tumors or CNS Metastases</td>
</tr>
<tr>
<td>9507</td>
<td>Phase I Study of Topotecan plus Cranial Radiation for Glioblastoma</td>
</tr>
<tr>
<td>9602</td>
<td>A Phase II Trial of Weekly Paclitaxel and Conventional Radiotherapy for Supratentorial Glioblastoma</td>
</tr>
<tr>
<td>9607</td>
<td>A Phase II Study of Radioprotection of Oral and Pharyngeal Mucosa by the Prostaglandin E&lt;sub&gt;1&lt;/sub&gt; Analog Misoprostol</td>
</tr>
<tr>
<td>9709</td>
<td>A Phase III Study to Test the Efficacy of the Prophylactic Use of Oral Pilocarpine to Reduce Hyposalivation and Mucositis Associated with Curative Radiation Therapy in Head and Neck Cancer Patients</td>
</tr>
<tr>
<td>9713</td>
<td>Phase III Randomized Study Comparing Best Supportive Care to Blafine® as a Prophylactic Agent for Radiation-Induced Skin Toxicity for Women Undergoing Breast Irradiation</td>
</tr>
<tr>
<td>9809</td>
<td>Phase III Study of Pentosanpolysulfate (PPS) in Treatment of GI Tract Sequelae of Radiotherapy</td>
</tr>
<tr>
<td>S-0120</td>
<td>A Randomized Phase I/II Study of Preoperative Radiotherapy with/without Sugen 5416 (NSC #696819; A TK Inhibitor Anti-Angiogenesis Compound) in the Management of Low to Intermediate Grade Soft Tissue Sarcoma of the Trunk or Extremity</td>
</tr>
<tr>
<td>S-0121</td>
<td>A Phase I/II Study of Neoadjuvant Chemotherapy, Angiogenesis Inhibitor SU5416 (NSC #696819; A TK Inhibitor Anti-Angiogenesis Compound), and Radiation Therapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall</td>
</tr>
</tbody>
</table>
DATE FAXED TO PI: ________________

Protocol and Information Office
PROTOCOL STATUS UPDATE

The Cancer Therapy Evaluation Program (CTEP), National Cancer Institute, as an Investigational New Drug (IND) sponsor, is required to review the status of each investigational agent on an ongoing basis. To help us update our records, prioritize resources and evaluate development plans for each agent, please complete the form below by checking the box that corresponds to the status of your study. Please FAX this page back to CTEP (301/496-9384) within 10 working days of receipt.

Principal Investigator: F. LeVeque, M.D.

NCI Protocol #: RTOG 97-09  Local #: RTOG 97-09  IND #: [Click here and type]

Protocol Title: A Phase III Study to Test the Efficacy of the Prophylactic Use of Oral Pilocarpine to Reduce Hyposalivation and Mucositis Associated with Curative Radiation Therapy in Head and Neck Cancer Patients

☐ ACTIVATED---Date: ________________
   The Cooperative Group/institution has decided to open the study for patient entry.

☐ TEMPORARILY CLOSED---Date: ________________
   A. Accrual has been temporarily suspended. Reason: Excessive toxicity
   B. Accrual has been temporarily suspended and patients are not receiving therapy.

☐ CLOSED---Date: ________________
   A. The protocol has been closed to patient accrual. Patients are still receiving therapy.
   B. The protocol has been closed to patient accrual. All patients have completed therapy, but are still being followed according to the primary objectives of the study. No additional investigational agents are needed for this study.

☐ ADMINISTRATIVELY COMPLETED---Date: ________________
   The protocol has been completed prematurely (e.g., due to poor accrual, insufficient drug supply, IND closure). The trial is closed to further accrual, and all patients have completed protocol treatment. A final study report/publication may not be possible.
   Reason for premature completion: ________________

☐ COMPLETED---Date: ________________
   The protocol has been closed to accrual, all patients have completed therapy, and the study has met its primary objectives. A final study report/publication is attached or has been submitted to CTEP. The minimal data requirements for this final study report include total accrual, adverse drug experiences and study results to date.

☒ X TERMINATED Date: October 18, 2002
   No further data collection required.

☐ Publication citation: ____________________________ or ☐ Publication in press

Beverly Kratzel
PRINTED NAME of person completing this form ____________________________ SIGNATURE ____________________________

Phone number: 215-574-3212 ____________________________ Date: 10-04-02 ____________________________

FAX to: 301/496-9384, ATTN: Protocol Specialist, PIO, CTEP, DCTD, NCI

PATS V1
MEMORANDUM

TO: RTOG Principal Investigators and CRAs

FROM: Elaine Pakuri
Director, Protocol Development

DATE: January 11, 2000

SUBJECT: Protocol Update

Activated

RTOG 99-02, “A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy with Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer”

Closing effective February 1, 2000

RTOG 95-14 Sarcoma Met Accrual
RTOG 97-09 Pilocarpine Met Accrual

cc: Study Chairs
ECOG (R9514)
SUMMARY OF CHANGES

RTOG 97-09 Pilocarpine

April 1, 1999

The following changes are in effect:

**Schema**
Metastases to the neck from an unknown primary are eligible provided the
dose to $\geq 50\%$ of the salivary gland is $\geq 50\ Gy$. This also affects the
Eligibility Checklist (Q1) and Section 3.1.1.

**Section 3.2.3**
Deleted “adrenergic antagonists” (also deleted from the Eligibility Checklist,
Q6).

**Section 4.1**
Requirement that the biopsy must be done within 6 weeks prior to study entry
was deleted.

**Sections 6.2 and 6.3** Clarified as follows:

6.2  **Technique**: Salivary glands should be included as part of the treatment field and
must be irradiated with opposed photon portals. Wedge-pair techniques that spare
mucosa on one side will be excluded except when used to boost the primary tumor.

6.3  **Dose**: The dose to $\geq 50\%$ of the salivary gland should be $\geq 50\ Gy$ given over 5 to
5 ½ weeks at 1.8-2 Gy once daily or 1.2 Gy b.i.d. $> 6$ hours apart, 5 days a week.

**Section 7.3.6**
McKesson’s address was added.

**Appendix VIII**
The direct fax number is (215) 574-0300.

*Replacement pages are attached.*
The following corrections have been made:

Section 3.2

Patients receiving concurrent chemotherapy with radiotherapy and/or registered to another RTOG treatment protocol for head and neck cancer ARE ELIGIBLE. This also affects the Schema and the Eligibility Checklist (Q12 & Q13). Section 3.2.8 and 3.2.9 were deleted.

Section 11.1

A followup CT scan is not required.

Replacement pages are attached.
SUMMARY OF CHANGES

RTOG 97-09 Pilocarpine

The following changes are in effect:

**Section 3.2** - Added

3.2.8 Concurrent chemotherapy

3.2.9 Patients registered to an RTOG treatment protocol for head and neck cancer.

These changes also affect the schema and the Eligibility Checklist (Q12-13)

**Section 6.3** - Changed to

"... central axis midplane minimum dose of 60 Gy over 6-7 weeks ... 5 days a week" (also affects the Schema)

**Section 11.3.2** (last line) Changed to

"Saliva should then collected for 5 minutes."

**Section 12.1** L4 and DP were corrected for text shift.

Replacement pages are attached.
MEMORANDUM

TO: RTOG Principal Investigators and CRAs

FROM: Elaine Pakulis
        Director, Protocol Development

DATE: March 17, 1998

SUBJECT: Protocol Update

Activated (available on the RTOG website 3/17/98)

RTOG 96-01, "A Phase III Trial of Radiation Therapy with or without Casodex in Patients with PSA Elevation Following Radical Prostatectomy for pT3N0 Carcinoma of the Prostate"

RTOG 97-09, "A Phase III Study to Test the Efficacy of the Prophylactic Use of Oral Pilocarpine to Reduce Hyposalivation and Mucositis Associated with Curative Radiation Therapy in Head and Neck Cancer Patients" - 1.0 Cancer Control credits per case.

Closed, effective immediately

RTOG 93-08 Frozen Tissue Bank Low Accrual
RTOG 93-04 Lung, β-interferon Met Objectives
RTOG 94-07 Soft Tissue Necrosis Low Accrual

Closing effective 3/31/98

RTOG 96-09 Small Cell Met Accrual

Revised (available on the RTOG Website on 3/17/98)

RTOG 95-08 Brain Mets Rev. #3
RTOG 95-12 T2 Larynx Rev. #2
RTOG 95-13 Topotecan Rev. #1
RTOG 96-08 N+ Prostate Rev. #1
RTOG 96-09 Small Cell Rev. #3
RTOG 97-05 Post Op Lung Rev. #1

Supported by the Division of Cancer Treatment, National Cancer Institute
Protocol Update
March 17, 1998
Page 2

Terminated. (no further data is due at RTOG for the following studies.)

RTOG 81-15  Rectal
RTOG 83-13  Head & Neck
RTOG 85-27  H & N/SR2508
RTOG 88-02  Bladder Adj.
RTOG 88-05  HFX Cervix
RTOG 88-06  CNS Lymphoma
RTOG 88-24  Post-op H&N
RTOG 89-08  HTA/RT Deep
RTOG 90-15  Lung: Chem/RT
RTOG 91-04  Brain Mets
RTOG 92-11  Tpot: H&N
RTOG 93-08  Tumor Repository

cc: Study Chairmen
A PHASE III STUDY TO TEST THE EFFICACY OF THE PROPHYLACTIC USE OF ORAL PILOCARPINE TO REDUCE HYPOSALIVATION AND MUCOSITIS ASSOCIATED WITH CURATIVE RADIATION THERAPY IN HEAD AND NECK CANCER PATIENTS

Study Chairman
Francis LeVeque, D.D.S.
Harper Hospital
Wayne State University
Section of Oral Medicine
3990 John R., 4WS Core
Detroit, Michigan 48201
(313) 745-9300
FAX# (313) 745-9302

Co-Chairman
Charles Scarantino, M.D., Ph.D.
(919) 783-3018
FAX# (919) 783-0737

Quality of Life
Jaqueline Fisher, R.N.
(313) 593-7335
FAX# (313) 593-8844

Activation Date:
March 17, 1998

Current Edition:
April 1, 1999
Includes Revisions 1-3

This protocol was designed and developed by the Radiation Therapy Oncology Group (RTOG) of the American College of Radiology (ACR). It is intended to be used only in conjunction with institution-specific IRB approval for study entry. No other use or reproduction is authorized by RTOG nor does RTOG assume any responsibility for unauthorized use of this protocol.
INDEX

Schema
Eligibility Check

1.0 Introduction

2.0 Objectives

3.0 Patient Selection

4.0 Pretreatment Evaluations

5.0 Registration Procedures

6.0 Radiation Therapy

7.0 Drug Therapy

8.0 Surgery

9.0 Other Therapy

10.0 Pathology

11.0 Patient Assessments

12.0 Data Collection

13.0 Statistical Considerations

References

Appendix I - Sample Consent Form
Appendix II - Karnofsky Performance Status
Appendix III - Staging System
Appendix IV - Toxicity Criteria
Appendix V - Adverse Reaction Reporting Guidelines
Appendix VI - Dental Evaluation
Appendix VII - Sample Portal Diagram
Appendix VIII - Study Agent Shipment Form
RADIATION THERAPY ONCOLOGY GROUP

RTOG 97-09

A PHASE III STUDY TO TEST THE EFFICACY OF THE PROPHYLACTIC USE OF ORAL PILOCARPINE TO REDUCE HYPOSALIVATION AND MUCOSITIS ASSOCIATED WITH CURATIVE RADIATION THERAPY IN HEAD AND NECK CANCER PATIENTS

SCHEMA

<table>
<thead>
<tr>
<th>S</th>
<th>RT Fractionation</th>
<th>R</th>
<th>Double-Blinded Randomization</th>
</tr>
</thead>
<tbody>
<tr>
<td>T</td>
<td></td>
<td>A</td>
<td>Pilocarpine Tablets, 5mg</td>
</tr>
<tr>
<td></td>
<td>1. Standard (once daily)</td>
<td>vs.</td>
<td>Placebo Tablets</td>
</tr>
<tr>
<td>R</td>
<td>2. Hyperfractionated</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td></td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>T</td>
<td></td>
<td>O</td>
<td>Both arms begin 3 days</td>
</tr>
<tr>
<td>I</td>
<td></td>
<td>M</td>
<td>prior to irradiation, one tablet four times a day for three months.* See Section 7.2.</td>
</tr>
<tr>
<td>F</td>
<td></td>
<td>I</td>
<td>Irradiation will be given at 1.8 to 2 Gy once a day or 1.2 Gy b.i.d &gt; 6 hours apart.</td>
</tr>
<tr>
<td>Y</td>
<td></td>
<td>Z</td>
<td>Total Minimum Dose: 60 Gy over 6-7 weeks.</td>
</tr>
<tr>
<td>E</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* After three months, all patients will receive non blinded pilocarpine for an additional three months.

Eligibility: (See Section 3.0 for details)

- Confirmed histopathologic diagnosis of oral or oropharyngeal squamous cell carcinoma; metastases to the neck from unknown primary provided the dose to ≥ 50% of the salivary gland is ≥ 50 Gy.
- Karnofsky Performance Score ≥ 60
- Age ≥ 18
- No prior radiotherapy to the head and neck
- Primary tumor in oral cavity or oropharynx
- No uncontrolled asthma, acute iritis, or narrow angle glaucoma
- Signed study-specific consent form

Required Sample Size: 244

9/8/98
1/8/99
4/1/99
<table>
<thead>
<tr>
<th>Institution #</th>
<th>RTOG 97-09</th>
<th>Case #</th>
<th>ELIGIBILITY CHECK (4/1/99)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(page 1 of 2)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Histologically confirmed diagnosis of oral cavity and/or oropharyngeal carcinoma or other site as specified in Section 3.1.1?

2. History or presence of salivary gland disease or salivary gland malignancy?

3. Prior irradiation to head or neck area?

4. Will the planned radiation therapy volume encompass ≥ 50% of the parotid glands and include an external beam dose of ≥ 50 Gy?

5. Any allergy to pilocarpine?

6. Any use of cholinergic drugs, anti-cholinergic drugs and tricyclic drugs?

7. Is the patient pregnant or lactating?

8. If there is childbearing potential, has the patient agreed to use an effective method of contraception?

9. What’s the patient’s age?

10. What is the Karnofsky Performance Score?

11. Does the patient have uncontrolled asthma, acute iritis, or narrow angle glaucoma?

**The following questions will be asked at Randomization:**

1. Has the Eligibility Checklist (above) been completed?

2. Is the patient eligible?

3. Date the study-specific Consent Form was signed? *(must be prior to randomization)*

   | Patient’s Name |
   | Verifying Physician |
   | Patient ID # |
   | Referring Institution # *(if different)* |

   Type of RT Fractionation *(standard vs. hyperfractionated)*

*(continued on next page)*
Institution #  
RTOC 97-09  
Case #  

ELIGIBILITY CHECK (4/1/99)  
(page 2 of 2)  

__________________________  
Birthdate  

__________________________  
Sex  

__________________________  
Race  

__________________________  
Social Security Number  

__________________________  
Zip Code *(9 digit if available)*  

__________________________  
Method of Payment  

__________________________  
Will any component of the patient's care be given at a VA or military facility?  

__________________________  
Treatment Start Date  

__________________________  
Treatment Assignment  

Completed by  ________________________________  

Date  ________________________________
1.0 INTRODUCTION

1.1 Background

An oral formulation of pilocarpine hydrochloride, a parasympathomimetic drug, has been shown in prospective randomized placebo-controlled clinical trials to increase salivary output and demonstrate significant subjective improvement in oral moisture and oral comfort in head and neck cancer patients following radiation therapy. Pilocarpine is a muscarinic agonist that has long been recognized as an effective salivary stimulant. It has also been shown that preemptive use of oral pilocarpine hydrochloride prior to and concurrent with therapeutic irradiation in head and neck cancer patients may have a positive effect upon retention of a beneficial level of post irradiation salivary function. A preliminary report by workers at the National Institutes of Health demonstrated decreases in salivary hypofunction and symptoms of xerostomia in five patients who were administered oral pilocarpine simultaneously with irradiation for treating head and neck neoplasms. It was postulated that functional stimulation of the salivary glands decreased radiation-induced damage to the glands by decreasing toxic products associated with cell death. The supposition is that partial elimination of oxygen free-radicals, lipid peroxidation and other oxidative debris would, by action of secretogogue-stimulated salivary lavage, decreases exposure of these toxic complexes to the salivary glands and thus afford a level of protection to them. Others have related possible radioprotection to prevention or moderation of radiation-induced apoptotic programming as measured by interactive regulation and expression of genes p53 and bcl-2. Based upon the work of van den Bremk and his co-investigators, one might also infer that prevention of indolent hyperamylasemia via moderation of amylase degranulation in acinar cells lends partial explanation to the mechanism(s) of salivary gland shielding and, by means of apoptotic events, a way of verifying these events during irradiation. However, at this juncture, there are no broadly identified explanations of exactly what dynamics occur at the cellular level of salivary glands when pilocarpine coexists with salivary flow when these glands are in propinquity to a tumor mass designated for curative radiation therapy.

1.2 Recent Studies

LeVeque et al. conducted a phase I pilot study using prophylactic oral pilocarpine tablets (5 mg/qid) in 12 head and neck cancer patients about to be treated with curative radiation therapy. To insure reasonable homogeneity among the study group, all patients had to have >50% of their parotid glands within the irradiation field and have >50 Gy delivered to that volume. Data from 10 evaluable patients completing the study (December 1994-July 1995) appear to indicate that: 1) The average retention of post-irradiation resting (unstimulated) whole saliva was 30% at 30 days and 28% at 45 days while the retention of stimulated whole saliva was 43% and 35%, respectively. 2) Post-irradiation subjective measurements of oral dryness recorded in this study group showed significant improvement over pre-irradiation baseline scores of the patient group enrolled in the pivotal therapeutic trials wherein a minimum of 4 months had to have elapsed from the completion of radiation therapy. Although not a study endpoint, oral mucosal changes were assessed during the course of the radiation therapy and it was discovered that there was notably less objective oral/oropharyngeal mucositis and significantly less mucositis-associated pain. 4) Investigators’ study notes reported that all of the patients demonstrated an early return to mucosal integrity and moisture, as compared to other matched patients. Later, Zimmerman et al. published a retrospective study comparing head and neck cancer patients who were given pilocarpine concurrently with radiation therapy to patients who were not. The comparisons were made by subjective assessments including oral dryness, oral comfort, ability to have uninterrupted sleep, ability to speak, and in eating. The pilocarpine group attained statistical superiority in all assessment comparisons individually and with the average of the combined assessments (p<0.01).

1.3 Quality of Life

Over the past decade there has been a dramatic increase in the use of Quality of Life measurement in clinical trials. This has evolved from the growing interest and focus on supportive care and comprehensive health outcomes. Improving the quality of patients’ lives has become as important as extending the quantity of life. The term, quality of life, refers to
"a patient’s appraisal of and satisfaction with their current level of functioning as compared to what they perceive to be possible or ideal". Since the dimensions of quality of life are subjective, they are best measured from the patient’s perspective. Recent advances in cancer treatments for locally controlling cancers of the head and neck have prompted clinicians to turn their attention to supporting and preserving their patients’ quality of life. Radiation therapy continues to be one of the primary modalities for treating head and neck cancers. Radiation-induced xerostomia remains an acute and commonly chronic complication of irradiation to the head and neck. It can produce pain and discomfort, increased cariogenesis, susceptibility to opportunistic oral infections, difficulty in speaking, chewing, swallowing and sleeping, and lifetime ageusia. These manifestations can lead to further problems of severe oral disease, nutritional deficiencies and an overall decline in homeostasis.

It is assumed that the relief of a symptom is valued because of its benefit to a patient’s functioning and well being. Equally important is evaluating the effectiveness of the intervention in translating into improvement in the quality of life (e.g., improved appetite, eating, etc.). In this study the focus will be two-fold: 1) to determine the impact of xerostomia on quality of life for patients receiving irradiation to the head and neck and, 2) the impact of symptom relief with pilocarpine as relates to quality of life.

2.0 OBJECTIVES
2.1 To determine if prophylactic use of pilocarpine can shelter unstimulated and stimulated whole salivary flow by objective measurement (sialometry).
2.2 To determine if prophylactic use of pilocarpine can moderate xerostomia as measured by subjective means.
2.3 To determine whether prophylactic use of pilocarpine can reduce the grade and duration of radiation-induced mucositis in the same patient group.
2.4 To evaluate quality of life outcomes between patients receiving pilocarpine to patients receiving placebo.
2.5 To evaluate the impact of xerostomia on patients receiving irradiation to the head and neck.

3.0 PATIENT SELECTION
3.1 Eligibility Criteria (4/1/99)
3.1.1 Confirmed histologically diagnosis of oral cavity and/or oropharyngeal carcinoma. Patients with unknown primary tumor metastatic to the neck, who are treated per Section 6.0 (treatment field to include ≥ 50% of salivary gland to a minimum of 50 Gy) are eligible.
3.1.2 Radiation volume to encompass ≥ 50% of parotid glands and have ≥ 50 Gy delivered to that volume via external beam.
3.1.3 Karnofsky Performance Score ≥ 60 (Appendix II).
3.1.4 Minimum age for entry, 18 years.
3.1.5 The patient must sign a study-specific informed consent prior to study entry (see Appendix I).
3.2 Ineligibility Criteria (9/8/98, 1/8/99, 4/1/99)
3.2.1 Salivary gland malignancy
3.2.2 Salivary gland disease, e.g., Sjögren’s syndrome.
3.2.3 Use of cholinergic drugs, anti-cholinergic drugs and tricyclic drugs.
3.2.4 Pregnant or lactating females are not eligible. Patients of childbearing potential should agree to use an effective method of contraception.
3.2.5 Prior head and neck irradiation.
3.2.6 Allergy to pilocarpine.
3.2.7 Patients with uncontrolled asthma, acute iritis, or narrow angle glaucoma.

4.0 PRETREATMENT EVALUATION (4/1/99)
4.1 Mandatory Evaluations (within 6 weeks prior to study entry)
4.1.1 Complete history and physical examination
4.1.2 Chest radiograph, PA and lateral
4.1.3 Diagram of lesion & nodes
4.1.4 CT scan of oral cavity/oropharynx with standard slice increments
4.2 **Mandatory Evaluations** *(within 4 weeks prior to study entry)*
4.2.1 Sialometry measuring unstimulated whole saliva
4.2.2 Sialometry measuring stimulated whole saliva
4.2.3 Objective, site-specific mucosal assessment
4.2.4 Objective mucosal assessment *(RTOG Scale)*
4.2.5 Subjective assessment of oral moisture
4.2.6 Subjective assessment of oral/oropharyngeal mucosal pain
4.3 **Other Evaluations** *(prior to any radiation therapy)*
4.3.1 Dental examination *(Appendix VI).* Patients should be advised that good oral hygiene should be well maintained especially during and after radiation therapy.
4.3.2 Complete QOL Head and Neck Symptom Questionnaire

5.0 **REGISTRATION PROCEDURES**
5.1 Each institution must submit a Study Agent Shipment Form *(Appendix VIII)* to RTOG Headquarters prior to the randomization of its first case. Allow adequate processing time *(7-10 days)* before calling to register your first case.
5.2 Patients can be registered only after pretreatment evaluation is completed and eligibility criteria are met. Patients are registered prior to any protocol therapy by calling RTOG headquarters at *(215) 574-3191,* Monday through Friday 8:30 am to 5:00 pm ET. The patient will be registered to a treatment arm and a case number will be assigned and confirmed by mail. **Online registration by the institution may not be used for this study.** The following information must be provided:
   - Institution Name & Number
   - Patient's Name & ID Number
   - Verifying Physician's Name
   - Eligibility Criteria Information
   - Stratification Information
   - Demographic Data
   - Treatment Start Date

6.0 **RADIATION THERAPY** *(9/8/98, 4/1/99)*
6.1 **Field:** Treatment portals must include > 50% of the oral cavity, oropharynx, or both. This will ensure inclusion of significant portions of the parotid glands so that ≥ 50% of the parotid glands receive ≥ 50 Gy. *(See Appendix VII)*
6.2 **Technique:** Salivary glands should be included as part of the treatment field and must be irradiated with opposed photon portals. Wedge-pair techniques that spare mucosa on one side will be excluded except when used to boost the primary tumor.
6.2.1 Patients may not be irradiated with homolateral electron beam or wedge-pair techniques.
6.3 **Dose:** The dose to ≥ 50% of the salivary gland should be ≥ 50 Gy given over 5 to 5½ weeks at 1.8-2 Gy once daily or 1.2 Gy b.i.d. > 6 hours apart, 5 days a week.
6.4 **Equipment:** Cobalt-60, 4 to 6 MV x-rays or any combination of these megavoltage beams is acceptable.
6.5 **Blocks:** Portal margins may be collimated or shaped using cerrobend blocks.
6.6 **Compensating or wedge filters:** Compensating or wedge filters should be used to assure dose homogeneity throughout the irradiated volume that is ± 5% of the central axis dose.
6.7 **Dose distribution:** A central axis distribution of radiation dose should be submitted for review.
6.8 **Timing with Study Drug:** See Section 7.2.

7.0 **DRUG THERAPY** *(DOUBLE-BLINDED)*
7.1 Pilocarpine *(IND 55,084)*
Pilocarpine hydrochloride *(proprietary name: Salagen Tablets®)* is a secretogogue that is FDA approved for treating post irradiation xerostomia in head and neck cancer patients. *Salagen*
Tablets® that will be used in this study are round small white 5 mg tablets that are stored at room temperature (59-86°F).

7.1.1 Pharmacokinetics and Metabolism
Pilocarpine hydrochloride tablets when ingested have an elimination half-life of 0.76 hours. Metabolism and elimination are thought to occur at neuronal synapses and probably in plasma. Pilocarpine and its degradation products are excreted in the urine.

7.1.2 Pharmacodynamics
Pilocarpine is a cholinergic parasympathomimetic agent that can exert a broad spectrum of action with predominant muscarinic action. Pilocarpine causes increased secretion by the exocrine glands including sweat, salivary, lachrymal, gastric, pancreatic, intestinal and mucosal cells of the respiratory and other mucosal tracts. Dose related smooth muscle stimulation can also occur. This can affect the intestinal, respiratory and urinary tracts. Ocular increase in parotid flow occurs within twenty minutes of dosing, peaks at one hour, and lasts approximately 3-5 hours. Pilocarpine hydrochloride tablets are contraindicated in patients with uncontrolled asthma and in patients with known sensitivity to pilocarpine.

7.1.3 Reported Side Effects
Previous studies have shown the more common effects of oral pilocarpine to be: sweating, urinary frequency, rhinitis, flushing, muscle tremors, nausea and vomiting, increased lacrimation and asthenia. No serious adverse experiences have been associated with the use of pilocarpine. Pilocarpine should be administered with caution in patients, and under close medical supervision, with significant cardiovascular disease, controlled asthma, chronic bronchitis, or chronic obstructive pulmonary disease requiring pharmacotherapy. In addition, the pharmacokinetics of pilocarpine in patients with renal and hepatic disease is unknown.

7.1.4 Effect of Pilocarpine upon the Cytotoxicity of Y-Radiation
A recent study was performed to determine whether pilocarpine affects the survival of squamous carcinoma cells (line SCC-25) following Y-radiation treatment. The survival of SCC-25 cells, after the exposure of cells to pilocarpine at concentration of 0-100 ng/ml given 0-1 hour prior to radiation at dose 0-20 Gy was determined by an in vitro colony formation assay. The survival fractions of SCC-25 cells were identical for the control and pilocarpine treated samples at all tested conditions. Calculated Do and Dq values did not depend on the presence of pilocarpine and were not affected by the time of incubation prior to irradiation. The results indicate that pilocarpine at clinically relevant concentrations, given to the SCC-25 cells 1 hour prior or at the time of irradiation did not affect survival of SCC-25 cells in vitro. It has been concluded that pilocarpine does not sensitize or protect these tumor cells form the effects of Y-radiation, suggesting that this agent should not compromise the tumoricidal effects of radiotherapy.

7.1.5 Formulation and Packaging and Storage
Pilocarpine will be supplied as 5 mg white tablets. Subjects randomized to placebo will receive matched placebo tablets. Pilocarpine and placebo will be provided in bottles of 100 tablets. All packages of pilocarpine and placebo should be stored securely in a dry place at room temperature.

7.2 Doses and Dose Modifications
7.2.1 Dosing Prior to Initiation of First Fraction: Beginning three days prior to irradiation, patients will be instructed to take one study tablet (double-blinded active drug or placebo) by mouth 4 times daily: at meals and before retiring. A study tablet must be taken by the patient 45-60 minutes prior to the start of RT; there should be 3-4 hours between study tablets.

7.2.2 Dosing During Course of Irradiation: In order to effect amylase degranulation at the optimal time, one study tablet should be given 45-60 minutes prior to each fraction during the course of irradiation. In the case of single fractions, the three additional scheduled tablets should be planned from the time of the prefraction dose. For instance, if the prefraction tablet is given at 14:00, the other tablets would likely be given at 10:00, 18:00, and 22:00 hours. In the case of b.i.d. fractions, a tablet should be given 45-60 minutes prior to each fraction, with the remaining two tablets each given approximately 3.5 to 4 hours from the prefraction tablets.
7.2.3 **Dosing After Completion of Radiation Therapy**: Upon completion of irradiation, patients should return to the original q.i.d. dosing schedule, i.e., at meals and before retiring.

7.2.4 **Dosing Break at Three Months Post irradiation**: At about 3 months from the start of radiation therapy, patients will stop taking the tablets for 3-4 days. This will allow for multiple half-life passages (mean elimination half-life for 5 mg pilocarpine = 0.76 hrs.). After the 3-4 day break, saliometric measurements will be repeated and subjective information will be collected as it was during the active phase of the study.

7.2.5 **Dosing, 3-6 Months**

After completion of the initial three month period, pilocarpine should be reinstated by physician prescription. Dosing schedules will be defined for each patient individually, based upon need for secretogogue therapy. Pilocarpine administration must be reported on the followup forms as "non-protocol treatment" with start and stop dates as applicable.

7.2.6 **Patient Compliance**

Patients must not miss more than three consecutive days of study drug, nor miss more than 15% of all scheduled doses during the course of irradiation. The pre-fraction pills (the ones taken 45-60 minutes prior to each fraction) must not be missed more than three (3) times in conventional fractionation, nor more than six (6) times in b.i.d fractionation.

7.2.7 **Dose Modification**

During treatment, the daily dose may be reduced from q.i.d. to t.i.d. in order to lessen side effects (usually sweating) should that occur. No increase above four tablets per day will be allowed.

7.2.8 **Salagen Information Helpline**

MGI provides an information Helpline for irradiated head and neck patients suffering with dry mouth and their Healthcare providers. Call (800) 644-4811 9:00 a.m. to 8 p.m. ET Monday through Friday. All calls are answered by a registered pharmacist and remain confidential.

7.3 **Supplier and Distribution**

7.3.1 Pilocarpine and placebo for the first three months of this trial will be provided by MGI Pharm, Inc. and distributed by McKesson BioServices. The non blinded administration of pilocarpine for the next three months will be by prescription (not supplied by MGI or McKesson).

7.3.2 Each institution must submit a Study Agent Shipment Form (Appendix VIII) to RTOG Headquarters prior to the randomization of its first case. Allow adequate processing time (7-10 days) before calling to register your first case.

7.3.3 After randomization, RTOG will provide the double-blinded treatment assignment to McKesson BioServices who will ship four bottles (100 tablets/bottle) of Salagen/Placebo to the randomizing institution by second day Federal Express or equivalent service. Study product for randomizations done after 2 p.m. will be shipped the following business day. For example, supplies for a 3 p.m. Friday randomization will be shipped on Monday (Tuesday, if Monday is a holiday).

7.3.4 Bottles will be numbered with the patient-specific double-blinded number assigned at randomization. The label will include the drug identification number, the RTOG case number, and the daily amount of drug to be taken. A complete protocol treatment course is three months.

7.3.5 Each bottle will also include the protocol number, packaging lot number, storage requirements and all necessary information required by Federal Regulations.

7.3.6 **Study Agent Accountability (4/1/99)**

Patients will be issued diaries to record daily doses. The reporting of drug administration will be based upon pill count. The number of pills dispensed, the number that the patient should have taken during the time period, and the number taken based on the pill count, will be recorded. The remaining pills will be returned to the patient after the pill count is recorded. At the completion of the three month period, all remaining study drug (and empty bottles) must be returned for a final count. Diary-indicated pill use and the number of pills the patient should have taken will be compared with the actual remaining pill count. Patients will be asked to bring in their diaries and unused pills. The number of pills dispensed minus the number of pills returned will indicate the number of pills taken. This number should correspond with the diary; however, any discrepancy should be investigated and reviewed with the patient and
ultimately with the principal investigator. There will be no combining of study drug used in the first three months with prescribed pilocarpine (*Salagen*) taken after three months. All unused product must be returned to McKesson BioServices.

**Attn:** Product Return/RTOG 97-09  
McKesson BioServices Pharmaceutical Services Division  
14665 Rothgeb Drive  
Rockville, MD 20850  
(301) 762-0069  

### 7.4 Adverse Drug Reaction Reporting  
7.4.1 The following guidelines for reporting adverse drug reactions (ADRs) apply to any research protocol which uses commercial agents. The following ADRs experienced by patients accrued to these protocols and attributed to the commercial agent(s) should be reported to the Investigational Drug Branch, Cancer Therapy Evaluation Program, within 10 working days:

7.4.1.1 Any ADR which is both serious (*life threatening, fatal*) and unexpected.

7.4.1.2 Any increased incidence of a known ADR which has been reported in the package insert or the literature.

7.4.1.3 Any death on study if clearly related to the commercial agent(s).

7.4.2 The ADR report should be documented on Form FDA 3500 (Appendix V) and mailed to the address on the form, to RTOG Headquarters and to:

Investigational Drug Branch  
P.O. Box 30012  
Bethesda, MD 20824  
Telephone (301) 230-2330  
available 24 hours  
fax (301) 230-0159

### 8.0 SURGERY  
Not applicable to this study.

### 9.0 OTHER THERAPY  
Not applicable to this study.

### 10.0 PATHOLOGY  
Not applicable to this study.

### 11.0 PATIENT ASSESSMENTS  
#### 11.1 Patient Evaluation (1/8/99)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Pre Rx</th>
<th>During Rx</th>
<th>At Followup</th>
<th>See Section 12.1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete history, P&amp;E</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>KPS and weight</td>
<td>X</td>
<td>x&lt;sup&gt;c&lt;/sup&gt;</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Biopsy</td>
<td>X</td>
<td></td>
<td>X&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>CT oral cavity/oropharynx</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dental Evaluation</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor Diagram</td>
<td>x&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toxicity Evaluation</td>
<td></td>
<td>x&lt;sup&gt;c&lt;/sup&gt;</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>QOL Assessment</td>
<td>X</td>
<td>x&lt;sup&gt;d&lt;/sup&gt;</td>
<td>x&lt;sup&gt;e&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Mucosal Assessment</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Sialometry</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Chest X-ray</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- a. for confirmation of recurrent tumor in the head and neck as applicable
- b. as applicable
c. weekly

d. week 4 of RT

e. at 3 and 6 months from start of RT

11.2 **Mucosal Reaction**

11.2.1 **Objective Scoring:** Visual signs of radiation mucositis will be independently assessed three times a week by the radiation oncologist using the RTOG and the protocol-specific scoring system. Separate assessments of those areas being irradiated, the pharyngeal wall, palate, buccal mucosa and lateral margin of the tongue will be made.

*Acute Effects of Radiation*

<table>
<thead>
<tr>
<th>Grade</th>
<th>Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No reaction</td>
</tr>
<tr>
<td>1</td>
<td>Injection (<em>erythema</em>), mild pain, no analgesics</td>
</tr>
<tr>
<td>2</td>
<td>patchy mucositis, moderate pain, ± analgesics</td>
</tr>
<tr>
<td>3</td>
<td>confluent mucositis, severe pain, ± narcotics</td>
</tr>
<tr>
<td>4</td>
<td>ulceration, hemorrhage, necrosis</td>
</tr>
</tbody>
</table>

11.3 **Objective Assessments, Sialometry**

11.3.1 **Unstimulated Whole Saliva**

During all collections, patients should be seated with eyes open and head tilted slightly forward and should be instructed to minimize orofacial movements and not to attempt to influence salivary flow (*such as by sucking or swallowing*). Just before the collection, the patient should be instructed to swallow. He/she should then be instructed to allow saliva to accumulate in the floor of the mouth for 60 seconds without swallowing. The patient should then spit the accumulated saliva into a pre-weighed 50 mL vial. The patient should repeat this procedure 4 more times for a total collection time of 5 minutes. Subjects should be instructed not to swallow during the entire collection procedure. These assessments will be made before initiation of the first radiation fraction, at the end of radiation therapy (< 10 days) and at approximately 3 and 6 months from start of irradiation.

11.3.2 **Stimulated Whole Saliva** (9/8/98)

To effect stimulation of salivary flow, two distinct methods are commonly used. One method uses an inert gum base to facilitate mechanical stimulation by the act of chewing at a measured pace over a set period of time. The other method relies upon gustatory stimulation. Both methods have been validated, however, the gustatory method will be used for this study as mechanical stimulation would not be comparable in dentate vs. recently edentulous patients. The technique used for gustatory stimulation relies upon use of a 2% citrate solution applied to the dorso-lateral borders of the tongue in the following manner: Patients will first empty their mouths of any saliva or mucus. It may be necessary to use a 4x4 sponge to aid in the removal of viscous material. Patients will then have 2% citrate solution applied, with cotton tipped applicators, to the lateral tongue bilaterally 5 times over a two minute period (0, 30, 60, 90 and 120 seconds). The mouth should then be emptied of retained citrate solution. Saliva should then be collected for 5 minutes. These assessments will be the same as for unstimulated saliva.

11.4 **Objective Assessments, Mucosa**

The oral/oropharyngeal mucosa will be assessed prior to the first radiation fraction. The baseline examination of the mucosa can be performed anytime from 10 days prior to the first day of radiation therapy. The mucosal examination will follow the RTOG format and a wholly objective site-specific grid. However, at baseline, any mucosal aberrations should be noted. These would include residual processes of healing from ablative surgery, areas of erythema, aphthous ulcerations, etc.

The grading of mucosal changes (*mucositis*) occurring during the course of irradiation will be performed thrice weekly (*Monday, Wednesday and Friday*). RTOG and oral mucosal site-specific tools will be used. It is imperative that some degree of consistency be maintained in the use of
these tools. Although it is not always possible to have the same examiner throughout the course of radiation therapy, it would be optimal to have personnel at each site calibrated to the intended specifics of the RTOG and site-specific gradations of mucositis.

11.5 Quality of Life

11.5.1 A patient self-assessed questionnaire has been selected. The components of the questionnaire include four domains of QOL and head and neck symptom-specific items. Because of the different focus of this study (intervention vs. disease outcome), the QOL assessments will include a baseline assessment, week 4 during RT and at 3 and 6 months from start of RT.

11.5.2.1 The questionnaire was developed by Hassan and Weymuller of the University of Washington, Seattle. This questionnaire was designed specifically to address problems incurred by head and neck cancer patients. The University of Washington QOL questionnaire was tested on 75 head and neck cancer patients. The questionnaire was compared to two established tools, the Karnofsky and the Sickness Impact Profile (SIP), for validity, acceptability, reliability and responsiveness. The overall results demonstrated the U of W HNSS tool to be equivalent to the Karnofsky and SIP for reliability, responsiveness, and was preferred test format for 97% of the tested patients. The scores on the HNSS correlated well with KPS and SIP indicating validity. The test-retest reliability coefficient was 0.95.

11.5.2.2 The selection of the U of W QOL tool is for its reference to specific symptom related effects (saliva, eating, taste, swallowing, pain) of the intervention of oral pilocarpine. The scale consists of ten symptom-specific categories each describes important daily living dysfunctions/limitations of head and neck cancer and the treatment outlined for this study. Each category has five possible item choices. The highest level or "normal" is scored 10 points while the lowest (or greatest dysfunction) is scored 50 points. The options between are in multiples of 10. The patient is asked to circle the statements which best describe their current status. The scores are totaled then adjusted to obtain the final range from 0 to 100. The higher the score, the greater the QOL, and conversely, the lower the score, the lower the QOL.

12.0 DATA COLLECTION

(RTOG, 1101 Market Street, Philadelphia, PA 19107, FAX#215/928-0153)

12.1 Summary of Data Submission

<table>
<thead>
<tr>
<th>Item</th>
<th>Due</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic Forms (A5)</td>
<td>Within 2 wks of study entry</td>
</tr>
<tr>
<td>Initial Evaluation Form (I1)</td>
<td></td>
</tr>
<tr>
<td>Diagnostic Pathology Report (P1)</td>
<td></td>
</tr>
<tr>
<td>Primary Site Staging Worksheet (I6)</td>
<td></td>
</tr>
<tr>
<td>Nodal Site Staging Worksheet (I7)</td>
<td></td>
</tr>
<tr>
<td>Pretreatment Symptom Scale Questionnaire (QL)</td>
<td></td>
</tr>
</tbody>
</table>

Preliminary Dosimetry Information

Protocol Treatment Form (RT Prescription) (T2)
Films (simulation and portal) (T3)
Calculations (T4)

Radiotherapy Form (T1)
Final Dosimetry Information
Daily Treatment record (T5)
Isodose Distribution (T6)
Boost Films (simulation and portal) (T8)

Sialometric Data Form (L4)
Patient Diary (DP)
Tissue Reaction Form (F2)

(must include pretreatment baseline assessments)
Study Specific Flowsheet (SF)

Within 2 wks after completion or termination of RT, and at 13 and 26 wks
Followup Symptom Scale Questionnaire (SS) At 4, 13 and 26 wks from start of RT
Follow-up Form (F1) At 13 and 26 wks from start of RT

13.0 STATISTICAL CONSIDERATIONS

13.1 Study Endpoints
13.1.1 The primary endpoint of this trial is the acute salivary gland toxicity.
13.1.2 This study will examine the acute mucositis in the pharynx, palate, tongue, or buccal.
13.1.3 Quality of life as measured using the University of Washington Head and Neck Symptom questionnaire.
13.1.4 This study will determine effects of continuing pilocarpine out to six months from start of treatment.

13.2 Sample Size

13.2.1 Mucositis Endpoint
The primary endpoint of this trial is the incidence of acute radiation salivary gland toxicity. RTOG 85-27 was a randomized phase III head and neck study where patients on the standard arm were treated with radiation therapy alone. The incidence of acute radiation salivary gland toxicity was:

<table>
<thead>
<tr>
<th>Grade of Salivary Gland Toxicity</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3-4</th>
</tr>
</thead>
<tbody>
<tr>
<td>19%</td>
<td>35%</td>
<td>46%</td>
<td>&lt;1%</td>
<td></td>
</tr>
</tbody>
</table>

Toxicity data is ordered categorical, and Whitehead's sample size formula for this type of data was employed. Assuming that the application of pilocarpine during and post radiotherapy reduces the incidence of grade 2 or worse salivary gland toxicity by 40%, we can estimate all probabilities as follows:

<table>
<thead>
<tr>
<th>Estimated Incidence on the Pilocarpine Arm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade of Salivary Gland Toxicity</td>
</tr>
<tr>
<td>0</td>
</tr>
<tr>
<td>34%</td>
</tr>
</tbody>
</table>

Setting the significance level at 95% and statistical power at 90% the estimated sample size is 233 patients. In order to ensure the required sample size is analyzable an additional five percent will be required to adjust for ineligible and unanalyzable (patients with no data submitted) cases. Therefore, 122 cases per arm will be required or a total of 244 randomized patients. This sample size will ensure an 90% ( =0.10, type II error) probability of detecting a 40% decrease in acute salivary gland toxicity while rejecting the null hypothesis at the 95% level ( =0.05, two-sided type I error).

13.2.2 Mucositis Endpoint
The secondary endpoint of this trial is the incidence of acute radiation mucositis. In RTOG 85-27 the incidence of acute radiation mucositis was:

<table>
<thead>
<tr>
<th>Grade of Mucositis</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
</tr>
<tr>
<td>14%</td>
</tr>
</tbody>
</table>

This is the worst severity observed in either the pharynx, palate, tongue, or buccal within 90 days from the start of radiotherapy. Assuming that the application of pilocarpine during and
post radiotherapy reduces the incidence of grade 3 and 4 mucositis by 40%, we can estimate all probabilities as follows:

<table>
<thead>
<tr>
<th>Estimated Incidence on the Pilocarpine Arm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade of Mucositis</td>
</tr>
<tr>
<td>0</td>
</tr>
<tr>
<td>31%</td>
</tr>
</tbody>
</table>

Setting the significance level at 95% and statistical power at 80% the estimated sample size is 200 patients. This is within the sample size required for the primary endpoint.

13.2.3 Quality of Life Endpoint
The possible benefit of pilocarpine is the reduction of salivary gland, and possibly mucositis toxicity; however, what value is this to the patient? Another endpoint of this trial is assessing the difference in quality of life between patients randomized to the two treatments. The University of Washington Head and Neck Symptom questionnaire summary score (HNSS) will be the primary variables of interest in assessing quality of life. With 233 evaluable patients there will be greater than 90% power to detect a difference of 10 in the average quality of life at the end of radiotherapy between the two treatments adjusted for their baseline value.

13.2.4 Patient Accrual
The following table displays the length of time necessary to accrue 244 patients given different average monthly accruals.

<table>
<thead>
<tr>
<th>Average Monthly Accrual</th>
<th>Time to Accrue 244 Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.0</td>
<td>1.7 years</td>
</tr>
<tr>
<td>11.0</td>
<td>1.8 years</td>
</tr>
<tr>
<td>10.0</td>
<td>2.1 years</td>
</tr>
<tr>
<td>9.0</td>
<td>2.3 years</td>
</tr>
</tbody>
</table>

The average monthly accrual is expected to be 10 patients per month, thus it will take 2.1 years to complete the accrual phase of this study. However, if the monthly accrual is less than 5 patients per month the feasibility will be re-evaluated.

13.2.5 Randomization Scheme
The treatment allocation will be done using a randomized permuted block within strata to balance patient factors other than institution. There will be a check on the balance of treatment assignments within each institution. Patients will be assigned with equal probability to each treatment by the RTOG.

13.2.6 Inclusion of Women and Minorities
In conformance with the National Institute of Health (NIH) Revitalization Act of 1993 with regard to inclusion of women and minority in clinical research, we make the following observations. The recursive partitioning analysis of the RTOG database for patients entered into operable head and neck trials failed to show any treatment interaction with gender. Analysis of the operable Intergroup study 0034 and RTOG 88-24 also failed to show a treatment interaction with gender. No information about race was collected in the RTOG Registry study and treatment studies prior to 1990. The SEER data suggest a difference in outcome by for patients treated for laryngeal cancer at a single institution was reported. The RTOG Special Population Committee is unaware of any other published data on patients with clinically localized head and neck cancer. Since there are no publications found to support a possible interaction between different radiation therapy schedules and either gender or race, the sample size will remain the same. The participation rates of minority participation are estimated below.
<table>
<thead>
<tr>
<th></th>
<th>American Indian or Alaskan Native</th>
<th>Asian or Pacific Islander</th>
<th>Black, not of Hispanic Origin</th>
<th>Hispanic</th>
<th>White, not of Hispanic Origin</th>
<th>Other or Unknown</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>0</td>
<td>1</td>
<td>7</td>
<td>2</td>
<td>38</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>Male</td>
<td>0</td>
<td>2</td>
<td>40</td>
<td>13</td>
<td>140</td>
<td>1</td>
<td>196</td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>0</td>
<td>3</td>
<td>47</td>
<td>15</td>
<td>178</td>
<td>1</td>
<td>244</td>
</tr>
</tbody>
</table>

### 13.3 Analysis Plans

#### 13.3.1 Interim Analyses of Accrual and Toxicity Data
Interim reports with statistical analyses will be prepared every six months until the initial paper reporting the treatment results has been submitted. In general, the interim reports will contain information about:

- the patient accrual rate with projected completion date for the accrual phase;
- the distribution of patients with respect to pretreatment characteristics;
- compliance rate of treatment delivery with respect to the protocol prescription;
- the frequency and severity of the toxicities not separated by treatment arm.

#### 13.3.2 Interim Analyses of Primary Study Points
There will be three interim analyses of acute radiation salivary gland and mucositis toxicity. The interim analyses will proceed according to the table below after all patients have been followed for three months. All endpoints will be tested independently at these significance levels.

<table>
<thead>
<tr>
<th>Total Accrual</th>
<th>Significance Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>25%</td>
<td>0.003</td>
</tr>
<tr>
<td>50%</td>
<td>0.004</td>
</tr>
<tr>
<td>75%</td>
<td>0.0049</td>
</tr>
<tr>
<td>100%</td>
<td>0.046 (final analysis)</td>
</tr>
</tbody>
</table>

If any of the interim analyses exceed the listed significance level, which were calculated to ensure an overall significance level of 0.05, then accrual will be terminated. The results of these interim analyses will be reported in a blinded fashion, only to the RTOG data monitoring committee as privileged communications. A report with recommendations will be given to the study chairman. Any problems or recommendations identified by the data monitoring committee, not results, will be reported to the head and neck committee, which responsible for this study and, if necessary, the CCOP and RTOG executive committees, so that corrective action can be taken.

#### 13.3.3 Analysis and Reporting of Initial Treatment Results
The major analysis will be undertaken when every patient has been potentially followed for a minimum of six months. The usual components of this analysis are:

- tabulation of all cases entered and any excluded from the analysis with the reasons for such exclusions;
- reporting institutional accrual;
- distribution of the important prognostic factors by assigned treatment;
- observed results with respect to the study endpoints.

The two-sided p-value of 0.046 will be used for comparing treatment arms, thus correcting for previous interim tests.
<table>
<thead>
<tr>
<th></th>
<th>American Indian or Alaskan Native</th>
<th>Asian or Pacific Islander</th>
<th>Black, not of Hispanic Origin</th>
<th>Hispanic</th>
<th>White, not of Hispanic Origin</th>
<th>Other or Unknown</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>0</td>
<td>1</td>
<td>7</td>
<td>2</td>
<td>38</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>Male</td>
<td>0</td>
<td>2</td>
<td>40</td>
<td>13</td>
<td>140</td>
<td>1</td>
<td>196</td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>0</td>
<td>3</td>
<td>47</td>
<td>15</td>
<td>178</td>
<td>1</td>
<td>244</td>
</tr>
</tbody>
</table>

### 13.3 Analysis Plans

#### 13.3.1 Interim Analyses of Accrual and Toxicity Data

Interim reports with statistical analyses will be prepared every six months until the initial paper reporting the treatment results has been submitted. In general, the interim reports will contain information about:

- the patient accrual rate with projected completion date for the accrual phase;
- the distribution of patients with respect to pretreatment characteristics;
- compliance rate of treatment delivery with respect to the protocol prescription;
- the frequency and severity of the toxicities not separated by treatment arm.

#### 13.3.2 Interim Analyses of Primary Study Points

There will be three interim analyses of acute radiation salivary gland and mucositis toxicity. The interim analyses will proceed according to the table below after all patients have been followed for three months. All endpoints will be tested independently at these significance levels.

<table>
<thead>
<tr>
<th>Total Accrual</th>
<th>Significance Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>25%</td>
<td>0.003</td>
</tr>
<tr>
<td>50%</td>
<td>0.004</td>
</tr>
<tr>
<td>75%</td>
<td>0.0049</td>
</tr>
<tr>
<td>100%</td>
<td>0.046 (final analysis)</td>
</tr>
</tbody>
</table>

If any of the interim analyses exceed the listed significance level, which were calculated to ensure an overall significance level of 0.05, then accrual will be terminated. The results of these interim analyses will be reported in a blinded fashion, only to the RTOG data monitoring committee as privileged communications. A report with recommendations will be given to the study chairman. Any problems or recommendations identified by the data monitoring committee, not results, will be reported to the head and neck committee, which responsible for this study and, if necessary, the CCOP and RTOG executive committees, so that corrective action can be taken.

#### 13.3.3 Analysis and Reporting of Initial Treatment Results

The major analysis will be undertaken when every patient has been potentially followed for a minimum of six months. The usual components of this analysis are:

- tabulation of all cases entered and any excluded from the analysis with the reasons for such exclusions;
- reporting institutional accrual;
- distribution of the important prognostic factors by assigned treatment;
- observed results with respect to the study endpoints.

The two-sided p-value of 0.046 will be used for comparing treatment arms, thus correcting for previous interim tests.
REFERENCES


25. Personal communication

APPENDIX I

RTOG 97-09

A PHASE III STUDY TO TEST THE EFFICACY OF THE PROPHYLACTIC USE
OF ORAL PILOPCARPINE TO REDUCE HYPOSALIVATION AND MUCOSITIS ASSOCIATED WITH
CURATIVE RADIATION THERAPY IN HEAD AND NECK
CANCER PATIENTS

Sample Patient Consent Form

RESEARCH STUDY

I have the right to know about the procedures that are used in my participation in clinical research so I have an opportunity to
decide whether or not to undergo the procedure after knowing the risks, benefits, and alternatives involved. This is to make
me better informed so I may give or withhold my consent to participate in clinical research.

PURPOSE OF THE STUDY

I have been diagnosed with cancer of the head and neck area. Radiation therapy has been recommended to treat this disease.
Radiation therapy is a form of cancer treatment using high energy x-rays. The method of giving the radiation therapy has
been discussed with me by my radiation oncologist.

One of the possible side effects of radiation therapy is a significant and permanent lessening of normal mouth moisture.
Although there are medications to treat dry mouth (caused by irradiated salivary gland) after radiation therapy, it might be
to protect the salivary glands during the radiation. Another side effect of radiation therapy given to the head and neck
region is sores in the mouth. This condition (radiation mucositis), can produce significant redness and painful ulcers. These
interfere with talking and eating for a period of several weeks during the radiation. Previous, but as yet unproved, studies
have shown that both dry mouth and radiation mucositis may be lessened by taking pilocarpine hydrochloride pills just
before and during the radiation therapy. So far, pilocarpine hydrochloride (Salagen) is an approved drug for treating dry
mouth after radiation therapy to the head and neck. This study will see whether oral pilocarpine for three months, including
during radiation, will be able to: 1) reduce the expected radiation mucositis and, 2) preserve oral moisture by protecting the
salivary glands during the radiation therapy. In addition, this study will attempt to see how I see the quality of my life before
treatment, during treatment, at the end of treatment and at intervals after completion of my treatment.

DESCRIPTION OF PROCEDURES

This study involves at random (by chance) assignment to one of two treatment arms. It is not clear at the present time which
of the two is better. For this reason the therapy which is to be offered to me will be based upon a the method of selection
called randomization. Randomization means that my physician will call a statistical office which will assign me one of the
two treatments by computer. The chance of my receiving one of the two therapies is approximately equal. I will be assigned
to one of the following:

- If I am assigned to this group, I will receive pilocarpine tablets 4 times a day beginning three days before
radiation therapy and continuing regularly for three months. Three days after I start the pills, I will start
radiation treatments once or twice a day, five days a week for 6-7 weeks. My physician will decide on whether
I get the once a day or twice a day schedule before I begin radiation treatments. At the three month time point,
I will be asked to continue with pilocarpine for an additional three months. The pharmaceutical company will
provide the pills for the first three months at no cost to me. The second three months will be by prescription at
either my expense or my insurance company's expense.

- If I am assigned to this group, I will receive a placebo (a non-active tablet) 4 times a day beginning three days
before radiation therapy, and continuing regularly for three months. Three days after I start the pills, I will start
radiation treatments once or twice a day, five days a week for 6-7 weeks. My physician will decide on whether
I get the once a day or twice a day schedule before I begin radiation treatments. At the three month time point,
I will be asked to start taking pilocarpine (not more placebo) for an additional three months. The pharmaceutical company will provide the pills for the first three months at no cost to me. The second three months will be by prescription at either my or my insurance company’s expense.

Study Evaluations

Salivary Flow
I will have my salivary flow measured before the first radiation therapy treatment, and within 10 days after completion of radiation therapy. It will also be measured at three and six months from the start of treatment. Salivary flow will be measured in two ways, unstimulated and stimulated. Unstimulated salivary flow samples are collected by emptying my mouth of saliva into a tube over a 5 minute period. Stimulated salivary flow samples are taken after a citrate solution on a cotton swab is rubbed on my tongue.

Oral Moisture
I will check my normal mouth moisture a few days before the first radiation treatment and during the radiation therapy. During the radiation, I will check for oral moisture three times a week using a diary that I will keep throughout the treatment. I will return the diary to the research staff at the end of my radiation. At approximately 3 and 6 months, I’ll check my oral moisture again.

Mucositis Grading
The lining of my mouth, lips, cheeks, tongue, palate, gum and denture-bearing areas will be examined by my physician or one of his/her research staff. They will check me before the first radiation treatment and then three times a week throughout the radiation therapy. After completion of the therapy, I will be examined again by the research staff with a bright penlight. Changes noted will be marked on a scoring sheet.

Mucositis Pain
Just as I checked my mouth moisture, I will also measure mouth pain when at rest and while speaking or eating. This will be done before, during and after radiation therapy also by use of a diary.

RISKS AND DISCOMFORTS

Drugs often have side effects. The drug used in this study, pilocarpine hydrochloride tablets, is a Food and Drug Administration (FDA)-approved agent for treating dry mouth caused with radiation therapy. It has been used after radiation treatments to the head and neck cancer are finished. It is marketed as Salagen. Not all of the side effects of this drug are known. Previous studies have shown the more common side effects to be sweating, watery eyes, urinary frequency, increased heart rate, muscle shaking, blurred vision, runny nose, dizziness, flushing, chills and tiredness. My physician will be checking me closely to see if any of these side effects are occurring. My physician will also be checking me closely if I have significant cardiovascular or lung disease treated with medication. The effect of Salagen in patients with liver or kidney disease is not known. Patients who have taken Salagen for long periods have tolerated its use well. This institution is not financially responsible for treatments of side effects caused by the study treatment.

There may be laboratory testing and procedures required by this study for research purposes. These additional tests may increase my medical bills although the impact will depend on my insurance company.

CONTACT PERSONS

In the event that injury occurs as a result of this research, treatment will be available. I understand, however, I will not be paid for medical care other than what my insurance carrier may provide. I will not receive other compensation. For more information concerning the research and research-related risks or injuries, I can notify Dr. ____________ the investigator in charge at __________________________. In addition, I may contact ____________ at __________________________ for information regarding patients’ rights in research studies.
BENEFITS

The treatment I am being offered has been established as safe and effective for stimulating salivary flow after radiation treatment for head and neck cancer. I may benefit by having some of my salivary gland tissue protected during radiation therapy. This may reduce my need for medication after radiation. I might also benefit by having less mucositis pain with radiation. This would allow me to continue the radiation more comfortably and without delays.

I have been told that should my disease become worse, should side effects become very severe, should new scientific developments occur that indicate the treatment is not in my best interest, or should my physician feel that this treatment is no longer in my best interest, the treatment would be stopped. Further treatment would be discussed.

ALTERNATIVES

There are no other proven treatments for protecting salivary function and/or preventing or lessening the mucositis associated with irradiation to the head and neck region. The pain of mucositis can be somewhat controlled by use of pain control medications. On occasion, if the mucositis becomes unbearable, my physician may stop the radiation for a few to several days to allow some mucosal healing.

I have been told that I should feel free to discuss my disease and my outcome with the doctor. The physician involved in my care will be available to answer any questions I have. In addition, I understand that I am free to ask my physician any questions concerning this program that I wish in the future.

My physician will explain procedures related to this protocol. Some of these procedures may result in added costs but may be covered by insurance. My doctor will discuss these with me.

VOLUNTARY PARTICIPATION

Participation in this study is voluntary. No compensation for participation other than free tablets for three months will be given. I understand that I am free to withdraw my consent to participate in this treatment program at any time. Refusal to participate will involve no penalty or loss of benefits. I am free to seek care from a physician of my choice at any time. If I do not take part in or withdraw from the study, I will continue to receive care. In the event of a research-related injury, I understand my participation has been voluntary.

CONFIDENTIALITY

Records of my progress while on the study will be kept in a confidential form at this institution and also in a computer file at the headquarters of the Radiation Therapy Oncology Group (RTOG). The confidentiality of the central computer record is carefully guarded. During their required reviews, representatives of the Food and Drug Administration (FDA), the National Cancer Institute (NCI), qualified representatives of applicable drug manufacturers, and other groups or organizations that have a role in the conduct of this study may have access to medical records which contain my identity. However, no information by which I can be identified will be released or published.

I have read all of the above, asked questions, received answers concerning areas I did not understand, and willingly give my consent to participate in this program. Upon signing this form I will receive a copy.

Patient Signature (or Legal Representative) ____________________________ Date _______
APPENDIX II

KARNOFSKY PERFORMANCE SCALE

100 Normal; no complaints; no evidence of disease
90 Able to carry on normal activity; minor signs or symptoms of disease
80 Normal activity with effort; some sign or symptoms of disease
70 Cares for self; unable to carry on normal activity or do active work
60 Requires occasional assistance, but is able to care for most personal needs
50 Requires considerable assistance and frequent medical care
40 Disabled; requires special care and assistance
30 Severely disabled; hospitalization is indicated, although death not imminent
20 Very sick; hospitalization necessary; active support treatment is necessary
10 Moribund; fatal processes progressing rapidly
0 Dead
APPE ndix III

AJCC STAGING
HEAD & NECK, 1997

STAGING-PRIMARY TUMOR (T)

TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ

ORAL CAVITY

Buccal mucosa
Lower alveolar ridge
Upper alveolar ridge
Retromolar gingiva (Retromolar trigone)
Floor of mouth
Hard palate
Anterior two-thirds of the oral tongue

T1 Tumor 2 cm or less in greatest dimension
T2 Tumor more than 2 cm but not more than 4 cm in greatest dimension
T3 Tumor more than 4 cm in greatest dimension
T4 Tumor invades adjacent structures (e.g. through cortical bone, into deep [extrinsic] muscle of tongue, maxillary sinus, skin. Superficial erosion of bone/tooth socket by gingival primary is not sufficient to classify as T4).

PHARYNX

Nasopharynx

Postero-superior walls
Lateral walls
Inferior (anterior) wall, consists of the superior surface of the soft palate

T1 Tumor confined to the nasopharynx
T2 Tumor extends to soft tissues of oropharynx and or nasal fossa
T2a without parapharyngeal extension
T2b with parapharyngeal extension
T3 Tumor invades bony structures and/or paranasal sinuses
T4 Tumor with intracranial extension and/or involvement of cranial nerves, infratemporal fossa, hypopharynx, or orbit.

Oropharynx

Faucial arch including soft palate, uvula and anterior tonsillar pillar
Glossotonsillar sulci and pharyngeal tonsils
Base of tongue
Pharyngeal wall including lateral and posterior walls and posterior tonsillar pillar

T1 Tumor 2 cm or less in greatest dimension
T2 Tumor more than 2 cm but not more than 4 cm in greatest dimension
T3 Tumor more than 4 cm in greatest dimension
T4 Tumor invades adjacent structures (e.g. pyterygoid muscle[s], mandible, hard palate, deep muscle of tongue, larynx)

Hypopharynx

Pyriform fossae
Postericoid region
Lateral and posterior hypopharyngeal walls

T1 Tumor limited to one subsite of hypopharynx and 2 cm or less in greatest dimension.
T2 Tumor invades more than one subsite of hypopharynx or an adjacent site, or measures more than 2 cm but not more than 4 cm in greatest diameter without fixation of hemilarynx.
T3 Tumor measures more than 4 cm in greatest dimension or with fixation of hemilarynx.
T4 Tumor invades adjacent structures (e.g. thyroid/cricoid cartilage, carotid artery, soft tissues of neck, prevertebral fascia/muscles, thyroid and/or esophagus).

LARYNX

Supraglottis

Suprahypoid epiglottis
Infrahypoid epiglottis
Aryepiglottic folds (laryngeal aspect)
Ventricular bands (false cords)
Arytenoids

T1 Tumor limited to one subsite of supraglottis with normal vocal cord mobility
T2 Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx.
T3 Tumor limited to larynx with vocal cord fixation and/or invades any of the following: postericoid area, pre-epiglottic tissues.
T4 Tumor extends through the thyroid cartilage, and/or extends into soft tissues of the neck, thyroid and/or esophagus.

Glottis

True vocal cords including anterior and posterior commissures

T1 Tumor limited to the vocal cord(s) (may involve anterior or posterior commissures) with normal mobility
T1a Tumor limited to one vocal cord
T1b Tumor involves both vocal cords
T2 Tumor extends to supraglottis and/or subglottis and/or with impaired vocal cord mobility
T3 Tumor limited to the larynx with vocal cord fixation
T4 Tumor invades through thyroid cartilage and/or extends to other tissues beyond the larynx (e.g., trachea, soft tissues of neck including thyroid, pharynx)

Subglottis

T1 Tumor limited to the subglottis
T2 Tumor extends to vocal cord(s) with normal or impaired mobility
T3 Tumor limited to larynx with vocal cord fixation
T4 Tumor invades through cricoid or thyroid cartilage and/or extends to other tissues beyond the larynx (e.g. trachea, or soft tissues of the neck including thyroid, esophagus)
REGIONAL LYMPH NODES (N) Excluding Nasopharynx

NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single ipsilateral node, 3 cm or less in greatest dimension.
N2 Metastasis in a single ipsilateral node, more than 3 cm, but not more than 6 cm in greatest dimension or multiple ipsilateral lymph nodes, none greater than 6 cm in greatest dimension, or bilateral or contralateral nodes, none more than 6 cm in greatest dimension.
N2a Metastasis in a single ipsilateral node more than 3 cm, but not more than 6 cm in greatest dimension.
N2b Metastasis in multiple ipsilateral nodes, none more than 6 cm in greatest dimension.
N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.
N3 Metastases in a lymph node more than 6 cm in greatest dimension.

REGIONAL LYMPH NODES (N) Nasopharynx Only

NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Unilateral metastasis in lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa
N2 Bilateral metastasis in lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa
N3 Metastasis in a lymph node(s)
   N3a greater than 6 cm in dimension
   N3b in the supraclavicular fossa

DISTANT METASTASIS (M)

MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis

STAGE GROUPING Excluding Nasopharynx

Stage 0 Tis, N0, M0
Stage I T1, N0, M0
Stage II T2, N0, M0
Stage III T3, N0, M0
   T1-3, N1, M0
Stage IVA T4, N0-1, M0
   Any T, N2, M0
Stage IVB Any T, N3, M0
Stage IVC Any T, Any N, M1

STAGE GROUPING Nasopharynx

Stage 0 Tis, N0, M0
Stage I T1, N0, M0
Stage IIA T2a, N0, M0
Stage IIB T1-T2a, N1, M0
   T2b, N0-1, M0
Stage III T1-T2b, N2, M0
   T3, N0-2, M0
Stage IVA T4, N0-2, M0
Stage IVB Any T, N3, M0
Stage IVC Any T, Any N, M1
Cooperative Group Common Toxicity Criteria

1. Toxicity grade should reflect the most severe degree occurring during the evaluated period, not an average.
2. When two criteria are available for similar toxicities, the one resulting in the more severe grade should be used.
3. Toxicity grade = 5 if that toxicity caused the death of the patient.

**INSTRUCTIONS**
4. Refer to detailed toxicity guidelines in the protocol, or to RTOG Headquarters for toxicity not covered on this table.
5. The evaluator must attempt to discriminate between disease/treatment and related signs/symptoms.
6. An accurate baseline prior to start of therapy is necessary.

<table>
<thead>
<tr>
<th>TOXICITY</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC</td>
<td>=&gt; 4.0</td>
<td>3.0 - 3.9</td>
<td>2.0 - 2.9</td>
<td>1.0 - 1.9</td>
<td>&lt; 1.0</td>
</tr>
<tr>
<td>Platelets</td>
<td>WNL</td>
<td>75.0 - normal</td>
<td>70.0 - 74.9</td>
<td>25.0 - 49.9</td>
<td>&lt; 25.0</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>WNL</td>
<td>10.0 - normal</td>
<td>8.0 - 10.0</td>
<td>6.5 - 7.9</td>
<td>&lt; 6.5</td>
</tr>
<tr>
<td>Granulocytes/Bands</td>
<td>=&gt; 2.0</td>
<td>1.5 - 1.9</td>
<td>1.0 - 1.4</td>
<td>0.5 - 0.9</td>
<td>&lt; 0.5</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>=&gt; 2.0</td>
<td>1.5 - 1.9</td>
<td>1.0 - 1.4</td>
<td>0.5 - 0.9</td>
<td>&lt; 0.5</td>
</tr>
<tr>
<td>Hemorrhage (Clinical)</td>
<td>None</td>
<td>Mild, no transfusion</td>
<td>Gross, 1-2 units transfusion per episode</td>
<td>Gross, 3-4 units transfusion per episode</td>
<td>Massive &gt; 4 units transfusion per episode</td>
</tr>
<tr>
<td>Infection</td>
<td>None</td>
<td>Mild</td>
<td>Moderate</td>
<td>Severe</td>
<td>Life-threatening</td>
</tr>
<tr>
<td>Nausea</td>
<td>None</td>
<td>Able to eat/reasonable intake</td>
<td>Intake significantly decreased but can eat</td>
<td>No significant intake</td>
<td>- - - - - - - - -</td>
</tr>
<tr>
<td>Vomiting</td>
<td>None</td>
<td>1 episode in 24 hrs.</td>
<td>2-5 episodes in 24 hrs.</td>
<td>6-10 episodes in 24 hrs.</td>
<td>&gt; 10 episodes in 24 hrs. requiring parenteral support</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>None</td>
<td>Increase of 2-3 stools per day over pre-Rx</td>
<td>Increase of 4-6 stools/day, or nocturnal stools, or moderate cramping</td>
<td>Increases of 7-9 stools/day or incontinence or severe cramping</td>
<td>Increase of =&gt; 10 stools/day or grossly bloody diarrhea, or need for parenteral support</td>
</tr>
<tr>
<td>Stomatitis</td>
<td>None</td>
<td>Painless ulcers, erythema or mild soreness</td>
<td>Painful erythema, edema or ulcers but can eat</td>
<td>Painful erythema, edema or ulcers and cannot eat</td>
<td>Requires parenteral or enteral support</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>WNL</td>
<td>- - - - - - -</td>
<td>&lt; 1.5 X N</td>
<td>1.5 - 3.0 X N</td>
<td>3.0 X N</td>
</tr>
<tr>
<td>Transaminase (SGOT, SGPT)</td>
<td>WNL</td>
<td>&lt;= 2.5 X N</td>
<td>2.6 - 5.0 X N</td>
<td>5.1 - 20.0 X N</td>
<td>&gt; 20.0 X N</td>
</tr>
<tr>
<td>Alkaline Phosphatase or S'nuclcotidase</td>
<td>WNL</td>
<td>&lt;= 2.5 X N</td>
<td>2.6 - 5.0 X N</td>
<td>5.1 - 20.0 X N</td>
<td>&gt; 20.0 X N</td>
</tr>
<tr>
<td>Liver/clinical</td>
<td>No change from baseline</td>
<td>- - - - - - -</td>
<td>- - - - - - -</td>
<td>Precoma</td>
<td>Hepatic coma</td>
</tr>
<tr>
<td>Creatinine</td>
<td>WNL</td>
<td>&lt; 1.5 X N</td>
<td>1.5 - 3.0 X N</td>
<td>3.1 - 6.0 X N</td>
<td>&gt; 6.0 X N</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>No change</td>
<td>1 + or &lt; 0.3 g% or &lt; 3 g/l</td>
<td>2 - 3+ or 0.3 - 1.0 g% or 3 - 10 g/l</td>
<td>4+ or &gt;1.0 g% or &gt;10 g/l</td>
<td>Nephrotic syndrome</td>
</tr>
<tr>
<td>Hematuria</td>
<td>Negative</td>
<td>Micro only</td>
<td>Gross/no clots</td>
<td>Gross + clots</td>
<td>Requires transfusion</td>
</tr>
<tr>
<td>TOXICITY</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>----------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Alopecia</td>
<td>No loss</td>
<td>Mild hair loss</td>
<td>Pronounced or total hair loss</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Pulmonary</td>
<td>None or no change</td>
<td>Asymptomatic with abnormality in PFT’s</td>
<td>Dyspnea on significant exertion</td>
<td>Dyspnea at normal level of activity</td>
<td>Dyspnea at rest</td>
</tr>
<tr>
<td>Cardiac dysrhythmias</td>
<td>None</td>
<td>Asymptomatic/transient/requiring no therapy</td>
<td>Recurrent or persistent/no therapy required</td>
<td>Requires treatment</td>
<td>Requires monitoring or hypotension or ventricular tachycardia or fibrillation</td>
</tr>
<tr>
<td>Cardiac function</td>
<td>None</td>
<td>Asymptomatic/decline of resting ejection fraction by 20% of baseline value</td>
<td>Asymptomatic/decline of resting ejection fraction by &gt;20% of baseline value</td>
<td>Mild CHF, responsive to therapy</td>
<td>Severe or refractory CHF</td>
</tr>
<tr>
<td>Cardiac/ischemia</td>
<td>None</td>
<td>Non-specific T-wave flattening</td>
<td>Asymptomatic/ST and T wave changes suggesting ischemia</td>
<td>Angina without evidence for infarction</td>
<td>Acute myocardial infarction</td>
</tr>
<tr>
<td>Cardiac/pericardial</td>
<td>None</td>
<td>Asymptomatic effusion/no intervention required</td>
<td>Pericarditis (rub, chest pain, ECG changes)</td>
<td>Symptomatic effusion: drainage required</td>
<td>Tamponade/drainage urgently required</td>
</tr>
<tr>
<td>Hypertension</td>
<td>None or no change</td>
<td>Asymptomatic/transient increase by &gt; 20 mmHg (D) or to &gt; 150/100 if previously WNL/No treatment required</td>
<td>Recurrent or persistent increase by &gt;20 mmHg (D) or to &gt; 150/100 if previously WNL/No treatment required</td>
<td>Requires therapy</td>
<td>Hypertensive crisis</td>
</tr>
<tr>
<td>Hypotension</td>
<td>None or no change</td>
<td>Changes requiring no therapy/including transient orthostatic hypotension</td>
<td>Requires fluid replacement or other therapy but not hospitalization</td>
<td>Requires therapy and hospitalization/resolves within 48 hours of stopping the agent</td>
<td>Requires therapy and hospitalization for &gt; 48 hours after stopping the agent</td>
</tr>
<tr>
<td>Neurological/sensory</td>
<td>None or no change</td>
<td>Mild paresthesias/loss of deep tendon reflexes</td>
<td>Mild or moderate objective sensory loss/moderate paresthesias</td>
<td>Severe objective sensory loss or paresthesias that interfere with function</td>
<td>---</td>
</tr>
<tr>
<td>Neurological/motor</td>
<td>None or no change</td>
<td>Subjective weakness/no objective findings</td>
<td>Mild objective weakness without significant impairment of function</td>
<td>Objective weakness with impairment of function</td>
<td>Paralysis</td>
</tr>
<tr>
<td>Neurological/cortical</td>
<td>None</td>
<td>Mild somnolence or agitation</td>
<td>Moderate somnolence or agitation</td>
<td>Severe somnolence, agitation, confusion, disorientation or hallucinations</td>
<td>Coma, seizures, toxic psychosis</td>
</tr>
<tr>
<td>Neurological/cerebellar</td>
<td>None</td>
<td>Slight incoordination/dysdiadokinesis</td>
<td>Intention tremor, dysmetria, slurred speech, nystagmus</td>
<td>Locomotor ataxia</td>
<td>Cerebellar necrosis</td>
</tr>
<tr>
<td>Neurological/mood</td>
<td>No change</td>
<td>Mild anxiety or depression</td>
<td>Moderate anxiety or depression</td>
<td>Severe anxiety or depression</td>
<td>Suicidal ideation</td>
</tr>
<tr>
<td>Neurological/headache</td>
<td>None</td>
<td>Mild</td>
<td>Moderate or severe but transient</td>
<td>Unrelenting and severe</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>--------------------------</td>
<td>--------------------------------</td>
<td>-----------------------------</td>
<td>----------------------------</td>
<td>-----------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td><strong>Neurological/constipation</strong></td>
<td>None or no change</td>
<td>Mild</td>
<td>Moderate</td>
<td>Severe</td>
<td>Lilleus &gt; 96 hours</td>
</tr>
<tr>
<td></td>
<td>Tinnitus</td>
<td>Hearing loss interfering</td>
<td>Deafness not correctable</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>with function but</td>
<td>with hearing aid</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Neurological/auditory</strong></td>
<td>None or no change</td>
<td>Asymptomatic/auditory</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>loss on audiology only</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Neurological/visual</strong></td>
<td>None or no change</td>
<td>Scattered macular or papular</td>
<td>Scattered macular or</td>
<td>Generalized symptomatic</td>
<td>Exfoliative dermatitis or</td>
</tr>
<tr>
<td></td>
<td>eruption or erythema that is</td>
<td>papular eruption or</td>
<td>papular eruption or</td>
<td>macular, papular, or</td>
<td>ulcerating dermatitis</td>
</tr>
<tr>
<td></td>
<td>asymptomatic</td>
<td>erythema with pruritis or</td>
<td>other associated symptoms</td>
<td>vesicular eruption</td>
<td></td>
</tr>
<tr>
<td><strong>Skin</strong></td>
<td>None or no change</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Transient rash/drug fever</td>
<td>Urticaria, drug fever =</td>
<td>Serum sickness, bronchospasm</td>
<td>Anaphylaxis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt; 38°C, 100.4°F</td>
<td>38°C, 100.4°F/mild</td>
<td>bronchospasm, requiring</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>38.1 - 40.0°C</td>
<td>parenteral medication</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Temperature</strong></td>
<td>None</td>
<td>37.1 - 38.0°C</td>
<td>38.1 - 40.0°C</td>
<td>&gt; 40.0°C/104.0°F for more</td>
<td>&gt; 40.0°C/104.0°F for more</td>
</tr>
<tr>
<td></td>
<td></td>
<td>98.7 - 100.4°F</td>
<td>100.5 - 104.0°F</td>
<td>than 24 hrs. or fever</td>
<td>than 24 hrs. or fever</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>accompanied by hypotension</td>
<td>accompanied by hypotension</td>
</tr>
<tr>
<td><strong>Local</strong></td>
<td>None</td>
<td>Pain</td>
<td>Pain and swelling with</td>
<td>Ulceration</td>
<td>Plastic surgery indicated</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>inflammation or phlebitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Weight gain/loss</strong></td>
<td>&lt; 5.0%</td>
<td>5.0 - 9.9%</td>
<td>10.0 - 19.9%</td>
<td>=&gt; 20.0%</td>
<td></td>
</tr>
<tr>
<td><strong>Hyperglycemia</strong></td>
<td>&lt; 116</td>
<td>116 - 160</td>
<td>161 - 250</td>
<td>251 - 500</td>
<td>&gt; 500 or ketoacidosis</td>
</tr>
<tr>
<td><strong>Hypoglycemia</strong></td>
<td>&gt; 54</td>
<td>55 - 64</td>
<td>40 - 54</td>
<td>30 - 39</td>
<td>&lt; 30</td>
</tr>
<tr>
<td><strong>Amylase</strong></td>
<td>WNL</td>
<td>&lt; 1.5 X N</td>
<td>1.5 - 2.0 X N</td>
<td>2.1 - 5.0 X N</td>
<td>&gt; 5.1 X N</td>
</tr>
<tr>
<td><strong>Hypocalcemia</strong></td>
<td>&lt; 10.6</td>
<td>10.6 - 11.5</td>
<td>11.6 - 12.5</td>
<td>12.6 - 13.5</td>
<td>=&gt; 13.5</td>
</tr>
<tr>
<td><strong>Hypomagnesemia</strong></td>
<td>&gt; 8.4</td>
<td>8.4 - 7.8</td>
<td>7.7 - 7.0</td>
<td>6.9 - 6.1</td>
<td>=&gt; 6.0</td>
</tr>
<tr>
<td><strong>Fibrinogen</strong></td>
<td>WNL</td>
<td>0.99 - 0.75 X N</td>
<td>0.74 - 0.50 X N</td>
<td>0.49 - 0.25 X N</td>
<td>=&gt; 0.24 X N</td>
</tr>
<tr>
<td><strong>Prothrombin time</strong></td>
<td>WNL</td>
<td>1.01 - 1.25 X N</td>
<td>1.26 - 1.50 X N</td>
<td>1.51 - 2.00 X N</td>
<td>=&gt; 2.00 X N</td>
</tr>
<tr>
<td><strong>Partial thromboplastin</strong></td>
<td>WNL</td>
<td>1.01 - 1.66 X N</td>
<td>1.67 - 2.33 X N</td>
<td>2.34 - 3.00 X N</td>
<td>=&gt; 3.00 X N</td>
</tr>
<tr>
<td></td>
<td>[0]</td>
<td>[1]</td>
<td>[2]</td>
<td>[3]</td>
<td>[4]</td>
</tr>
<tr>
<td>-------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>SKIN</strong></td>
<td>No change over baseline</td>
<td>Follicular, faint or dull erythema / epilation / dry desquamation / decreased sweating</td>
<td>Tender or bright erythema, patchy moist desquamation / moderate edema</td>
<td>Confluent, moist desquamation other than skin folds, pitting edema</td>
<td>Ulceration, hemorrhage, necrosis</td>
</tr>
<tr>
<td><strong>MUCOUS MEMBRANE</strong></td>
<td>No change over baseline</td>
<td>Injection / may experience mild pain not requiring analgesic</td>
<td>Patchy mucositis which may produce an inflammatory serosanguinous discharge / may experience moderate pain requiring analgesia</td>
<td>Confluent fibrinous mucositis / may include severe pain requiring narcotic</td>
<td>Ulceration, hemorrhage or necrosis</td>
</tr>
<tr>
<td><strong>EYE</strong></td>
<td>No change</td>
<td>Mild conjunctivitis with or without keratitis requiring steroids &amp;/or antibiotics / dry eye requiring artificial tears / iritis with photophobia</td>
<td>Moderate conjunctivitis with or without keratitis requiring steroids &amp;/or antibiotics</td>
<td>Severe keratitis with corneal ulceration / objective decrease in visual acuity or in visual fields / acute glaucoma / panophthalmitis</td>
<td>Loss of vision (unilateral or bilateral)</td>
</tr>
<tr>
<td><strong>EAR</strong></td>
<td>No change over baseline</td>
<td>Mild external otitis with erythema, pruritis, secondary to dry desquamation not requiring medication. Audiogram unchanged from baseline</td>
<td>Moderate external otitis requiring topical medication/ serous otitis medius/ hypoaacusis on testing only</td>
<td>Severe external otitis with discharge or moist desquamation / symptomatic hypoaacusis/ tinnitus, not drug related</td>
<td>Deafness</td>
</tr>
<tr>
<td><strong>SALIVARY GLAND</strong></td>
<td>No change over baseline</td>
<td>Mild mouth dryness/ slightly thickened saliva/ may have slightly altered taste such as metallic taste/ these changes not reflected in alteration in baseline feeding behavior, such as increased use of liquids with meals</td>
<td>Moderate to complete dryness / thick, sticky saliva / markedly altered taste</td>
<td>----------------------------------------</td>
<td>Acute salivary gland necrosis</td>
</tr>
<tr>
<td><strong>PHARYNX &amp; ESOPHAGUS</strong></td>
<td>No change over baseline</td>
<td>Mild dysphagia or odynophagia/ may require topical anesthetic or non-narcotic analgesics/ may require soft diet</td>
<td>Moderate dysphagia or odynophagia/ may require narcotic analgesics/ may require puree or liquid diet</td>
<td>Severe dysphagia or odynophagia with dehydration or weight loss &gt;15% from pre-treatment baseline) requiring N-G feeding tube, T.V. fluids or hyperalimentation</td>
<td>Complete obstruction, ulceration, perforation, fistula</td>
</tr>
<tr>
<td><strong>LARYNX</strong></td>
<td>No change over baseline</td>
<td>Mild or intermittent hoarseness/ cough not requiring antitussive/ erythema of mucosa</td>
<td>Persistent hoarseness but able to vocalize / referred ear pain, sore throat, patchy fibrinous exudate or mild arytenoid edema not requiring narcotic/cough requiring antitussive</td>
<td>Whispered speech, throat pain or referred ear pain requiring narcotic/ confluent fibrinous exudate, marked arytenoid edema.</td>
<td>Marked dyspnea, stridor or hemoptysis with tracheostomy or intubation necessary</td>
</tr>
<tr>
<td><strong>UPPER G.I.</strong></td>
<td>No change</td>
<td>Anorexia with &lt;= 5% weight loss from pretreatment baseline/ nausea not requiring antiemetics/ abdominal discomfort not requiring parasympatholytic drugs or analgesics</td>
<td>Anorexia with &lt;=15% weight loss from pretreatment baseline/ nausea &amp;/or vomiting requiring antiemetics/abdominal pain requiring analgesics</td>
<td>Anorexia with &gt;15% wt loss from pretreatment baseline or requiring N-G tube or parenteral support. Nausea &amp;/or vomiting requiring tube or parenteral support/ abdominal pain, severe despite medication/ hematemesis or melena/ abdominal distention (flat plate radiograph demonstrates distended bowel loops)</td>
<td>Ileus, subacute or acute obstruction, perforation, GI bleeding requiring transfusion/ abdominal pain requiring tube decompression or bowel diversion.</td>
</tr>
<tr>
<td>LOWER G.I. INCLUDING PELVIS</td>
<td>[ 0 ]</td>
<td>[ 1 ]</td>
<td>[ 2 ]</td>
<td>[ 3 ]</td>
<td>[ 4 ]</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td>No change</td>
<td>Increased frequency or change in quality of bowel habits not requiring medication / rectal discomfort not requiring analgesics</td>
<td>Diarrhea requiring parasympatholytic drugs (e.g., Lomotil) / mucous discharge not necessitating sanitary pads / rectal or abdominal pain requiring analgesics</td>
<td>Diarrhea requiring parenteral support / severe mucous or blood discharge necessitating sanitary pads / abdominal distention (flattened radiograph demonstrates distended bowel loops)</td>
<td>Acute or subacute obstruction, fistula or perforation; GI bleeding requiring transfusion; abdominal pain or tenesmus requiring tube decompression or bowel diversion</td>
<td></td>
</tr>
<tr>
<td>LUNG</td>
<td>No change</td>
<td>Mild symptoms of dry cough or dyspnea on exertion</td>
<td>Persistent cough unresponsive to narcotic antitussive agent or dyspnea at rest / clinical or radiologic evidence of acute pneumonitis / intermittent oxygen or steroids may be required</td>
<td>Severe respiratory insufficiency / continuous oxygen or assisted ventilation</td>
<td></td>
</tr>
<tr>
<td>GENITOURINARY</td>
<td>No change</td>
<td>Frequency of urination or nocturia twice pretreatment habit / dysuria, urgency not requiring medication</td>
<td>Frequency of urination or nocturia which is less frequent than every hour. Dysuria, urgency, bladder spasm requiring local anesthetic (e.g. Pyridium)</td>
<td>Frequency with urgency and nocturia hourly or more frequently / dysuria, pelvis pain or bladder spasm requiring regular, frequent narcotic / gross hematuria with / without clot passage</td>
<td>Hematuria requiring transfusion / acute bladder obstruction not secondary to clot passage, ulceration or necrosis</td>
</tr>
<tr>
<td>HEART</td>
<td>No change over baseline</td>
<td>Asymptomatic but objective evidence of EKG changes or pericardial abnormalities without evidence of other heart disease</td>
<td>Symptomatic with EKG changes and radiologic findings of congestive heart failure or pericardial disease / no specific treatment required</td>
<td>Congestive heart failure, angina pectoris, pericardial disease responding to therapy</td>
<td>Congestive heart failure, angina pectoris, pericardial disease, arrhythmias not responsive to non-surgical measures</td>
</tr>
<tr>
<td>CNS</td>
<td>No change</td>
<td>Fully functional status (i.e., able to work) with minor neurologic findings, no medication needed</td>
<td>Neurologic findings present sufficient to require home care / nursing assistance may be required / medications including steroids/ anti-seizure agents may be required</td>
<td>Neurologic findings requiring hospitalization for initial management</td>
<td>Serious neurologic impairment which includes paralysis, coma or seizures &gt; 3 per week despite medication / hospitalization required</td>
</tr>
</tbody>
</table>

| HEMATOLOGIC WBC (X 1000) | => 4.0 | 3.0 - < 4.0 | 2.0 - < 3.0 | 1.0 - < 2.0 | < 1.0 |
| PLATELETS (X 1000)       | > 100  | 75 - < 100  | 50 - < 75   | 25 - < 50  | < 25 or spontaneous bleeding |
| NEUTROPHILS (X 1000)     | => 1.9 | 1.5 - < 1.9 | 1.0 - < 1.5 | 0.5 - < 1.0 | < 0.5 or sepsis |
| HEMOGLOBIN (GM %)         | > 11   | 11 - 9.5   | < 9.5 - 7.5 | < 7.5 - 5.0 | --------------- |
| HEMATOCRIT (%)            | => 32  | 28 - < 32  | < 28        | Packed cell transfusion required | --------------- |

GUIDELINES: The acute morbidity criteria are used to score/rate toxicity from radiation therapy. The criteria are relevant from day 1, the commencement of therapy, through day 90. Thereafter, the EORTC/RTOG Criteria of Late Effects are to be utilized.

The evaluator must attempt to discriminate between disease and treatment related signs and symptoms.

An accurate baseline evaluation prior to commencement of therapy is necessary.

All toxicities Grade 3,4 or 5' must be verified by the Principal Investigator

* ANY TOXICITY WHICH CAUSED DEATH IS GRADED 5.
<table>
<thead>
<tr>
<th>ORGAN TISSUE</th>
<th>0</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>SKIN</td>
<td>None</td>
<td>Slight atrophy; Pigmentation changes; Some hair loss</td>
<td>Patchy atrophy; Moderate telangiectasia; Total hair loss</td>
<td>Market atrophy; Gross telangiectasia</td>
<td>Ulceration</td>
</tr>
<tr>
<td>SUBCUTANEOUS TISSUE</td>
<td>None</td>
<td>Slight induration (fibrosis) and loss of subcutaneous fat</td>
<td>Moderate fibrosis but asymptomatic; Slit field contracture &lt;10% linear reduction</td>
<td>Severe induration and loss of subcutaneous tissue; Slit field contracture &gt;10% linear measurement</td>
<td>Nocrosis</td>
</tr>
<tr>
<td>MUCOUS MEMBRANE</td>
<td>None</td>
<td>Slight atrophy and dryness</td>
<td>Moderate atrophy and telangiectasia; Little mucous</td>
<td>Marked atrophy with complete dryness; Severe telangiectasia</td>
<td>Ulceration</td>
</tr>
<tr>
<td>SALIVARY GLANDS</td>
<td>None</td>
<td>Slight dryness of mouth; Good response on stimulation</td>
<td>Moderate dryness of mouth; Poor response on stimulation</td>
<td>Complete dryness of mouth; No response on stimulation</td>
<td>Fibrosis</td>
</tr>
<tr>
<td>SPINAL CORD</td>
<td>None</td>
<td>Mild L'Hermitte's syndrome</td>
<td>Severe L'Hermitte's syndrome</td>
<td>Objective neurological findings at or below cord level treated</td>
<td>Mono, para quadraplegia</td>
</tr>
<tr>
<td>BRAIN</td>
<td>None</td>
<td>Mild headache; Slight lethargy</td>
<td>Moderate headache; Great lethargy</td>
<td>Severe headaches; Severe CNS dysfunction (partial loss of power or dyskinesia)</td>
<td>Seizures or paralysis</td>
</tr>
<tr>
<td>EYE</td>
<td>None</td>
<td>Asymptomatic cataract; Minor corneal ulceration or keratitis</td>
<td>Symptomatic cataract; Moderate corneal ulceration; Minor retinopathy or glaucoma</td>
<td>Severe keratitis; Severe retinopathy or detachment; Severe glaucoma</td>
<td>Panophthalmitis / Blindness</td>
</tr>
<tr>
<td>LARYNX</td>
<td>None</td>
<td>Hoarseness; Slight arytenoid edema</td>
<td>Moderate arytenoid edema; Chondritis</td>
<td>Severe edema; Severe chondritis</td>
<td>Nocrosis</td>
</tr>
<tr>
<td>LUNG</td>
<td>None</td>
<td>Asymptomatic or mild symptoms (dry cough); Slit radiographic appearances</td>
<td>Moderate asymptomatic fibrosis or pneumonitis (severe cough); Low grade fever; Patchy radiographic appearances</td>
<td>Severe asymptomatic fibrosis or pneumonitis Dense radiographic changes</td>
<td>Severe respiratory insufficiency / Continuous O2 / Assisted ventilation</td>
</tr>
<tr>
<td>HEART</td>
<td>None</td>
<td>Asymptomatic or mild symptoms; Transient T wave inversion &amp; ST changes; sinus tachycardia &gt;110 (at rest)</td>
<td>Moderate angina on effort; Mild paracarditis; Normal heart size; Persistent abnormal T wave and ST changes; Low QRs</td>
<td>Severe angina; Pericardial effusion; Constrictive pericarditis; Moderate heart failure; Cardiac enlargement; EKG abnormalities</td>
<td>Tamponade / Severe heart failure / Severe constrictive pericarditis</td>
</tr>
<tr>
<td>ESOPHAGUS</td>
<td>None</td>
<td>Mild fibrosis; Slight difficulty in swallowing solids; No pain on swallowing</td>
<td>Unable to take solid food normally; Swallowing semi-solid foods; Distillation may be indicated</td>
<td>Severe fibrosis; Able to swallow only liquids; May have pain on swallowing; Dilatation required</td>
<td>Nocrosis / Perforation Fistula</td>
</tr>
<tr>
<td>SMALL / LARGE INTESTINE</td>
<td>None</td>
<td>Mild diarrhea; Mild cramping; Bowel movement 5 times daily; Slight rectal discharge or bleeding</td>
<td>Moderate diarrhea and colitis; Bowel movement &gt;5 times daily; Excessive rectal mucus or intermittent bleeding</td>
<td>Obstruction or bleeding, requiring surgery</td>
<td>Nocrosis / Perforation Fistula</td>
</tr>
<tr>
<td>LIVER</td>
<td>None</td>
<td>Mild lassitude; Nausea, dyspnoea; Slightly abnormal liver function</td>
<td>Moderate symptoms; Some abnormal liver function tests; Serum albumin normal</td>
<td>Disabling hepatic insufficiency; Liver function tests grossly abnormal; Low albumin; Edema or ascites</td>
<td>Nocrosis / Hepatic coma or encephalopathy</td>
</tr>
<tr>
<td>KIDNEY</td>
<td>None</td>
<td>Transient albuminuria; No hypertension; Mild impairment of renal function; Urea 25-35 mg/dl; Creatinine 1.5-2.0 mg/dl; Creatinine clearance &gt;75%</td>
<td>Persistent moderate albuminuria (2+); Mild hypertension; No related anemia; Moderate impairment of renal function; Urea &gt;36-60 mg/dl; Creatinine clearance (50-74%)</td>
<td>Severe albuminuria; Severe hypertension Persistent anemia (&gt;10%); Severe renal failure; Urea &gt;50 mg/dl; Creatinine &gt;4.0 mg/dl; Creatinine clearance &lt;50%</td>
<td>Malignant hyptension Uremic coma / Urea &gt; 100%</td>
</tr>
<tr>
<td>BLADDER</td>
<td>None</td>
<td>Slight epithelial atrophy; Minor telangiectasia (microscopic hematuria)</td>
<td>Moderate frequency generalized telangiectasia Intermittent macroscopic hematuria</td>
<td>Severe frequency &amp; dysuria Severe generalized telangiectasia (often with petechiae); Frequent hematuria; Reduction in bladder capacity (&lt;150 cc)</td>
<td>Nocrosis / Contracted bladder capacity (&lt;100 cc) Severe hemorrhagic cystitis</td>
</tr>
<tr>
<td>BONE</td>
<td>None</td>
<td>Asymptomatic; No growth retardation; Reduced bone density</td>
<td>Moderate pain or tenderness; Growth retardation; Irregular bone sclerosis</td>
<td>Severe pain or tenderness; Complete arrest of bone growth; Dense bone sclerosis</td>
<td>Nocrosis / Spontaneous fracture</td>
</tr>
<tr>
<td>JOINT</td>
<td>None</td>
<td>Mild joint stiffness; Slight limitation of movement</td>
<td>Moderate stiffness intermittent or moderate joint pain; Moderate limitation of movement</td>
<td>Severe joint stiffness; Pain with severe limitation of movement</td>
<td>Nocrosis / Complete fixation</td>
</tr>
</tbody>
</table>
APPENDIX V

ADVERSE EVENT REPORTING GUIDELINES

A. GENERAL GUIDELINES

In order to assure prompt and complete reporting of toxicities, the following general guidelines are to be observed. These apply to all RTOG studies and Intergroup Studies in which RTOG participates. When a protocol toxicity requires more intense, special handling, study-specific reporting procedures supersede the General Guidelines.

1. The Principal Investigator will report the details of any unusual, significant, fatal or life-threatening protocol treatment reaction to the RTOG Group Chairman and to the Headquarters Data Management Staff (215/574-3214) within 24 hours of discovery. When telephone reporting is required, the Principal Investigator should have all relevant material available. See the protocol-specific criteria to grade the severity of the reaction.

   a. All deaths during protocol treatment or within 30 days of completion or termination of protocol treatment regardless of cause requires telephone notification within 24 hours of discovery.

2. The Principal Investigator will also report the details of the significant reaction to the Study Chairman by telephone.

3. A written report, including all relevant study forms, containing all relevant clinical information concerning the reported event will be sent to RTOG Headquarters by the Principal Investigator. This must be sent within 10 working days of the discovery of the toxicity unless specified sooner by the protocol (FAX #215/928-0153).

4. The Group Chairman in consultation with the Study Chairman will take appropriate and prompt action to inform the membership and statistical personnel of any protocol modifications and/or precautionary measures if this is warranted.

5. For those incidents requiring telephone reporting to the National Cancer Institute (NCI), Investigational Drug Branch (IDB) or Food and Drug Administration (FDA), the Principal Investigator should first call RTOG (as outlined above) unless this will unduly delay the notification process required by the federal agencies.

   A copy of all correspondence submitted to NCI, or to another Cooperative Group (in the case of RTOG-coordinated intergroup studies) must also be submitted to RTOG Headquarters when applicable.

6. The Principal Investigator, when participating in RTOG-coordinated Intergroup studies, is obligated to comply with all additional reporting specifications required by an individual study.

7. Institutions must also comply with their individual Institutional Review Board policy with regard to toxicity reporting procedure.

8. Failure to comply with reporting requirements in a timely manner may result in suspension of patient registration.

B. RADIATION TOXICITY GUIDELINES

1. All fatal toxicities (grade 5) resulting from protocol treatment must be reported by telephone to the Group Chairman, to RTOG Headquarters Data Management and to the primary Study Chairman within 24 hours of discovery.

2. All life-threatening (grade 4) toxicities resulting from protocol treatment using non-standard fractionated treatment, brachytherapy, radiopharmaceuticals and radiosurgery must be reported by telephone to the Group Chairman, to RTOG Headquarters Data Management and to the primary Study Chairman within 24 hours of discovery.
3. Appropriate data forms, and if requested a written report, must be submitted to Headquarters within 10 working days of the telephone report.

C. ADVERSE DRUG REACTIONS - DRUG AND BIOLOGICS

An adverse reaction is a toxicity or an undesirable effect usually of severe nature. Specifically, this may include major organ toxicities of the liver, kidneys, cardiovascular system, central nervous system, skin, bone marrow, or anaphylaxis. These undesirable effects may be further classified as "known" or "unknown" toxicities.

Known toxicities are those which have been previously identified as having resulted from administration of the agent. They may be identified in the literature, the protocol, the consent form or noted in the drug insert.

Unknown toxicities are those thought to have resulted from the agent but have not previously been identified as a known side effect.

Commercial and Non-Investigational Agents

i. Any fatal (grade 5) or life threatening (grade 4) adverse reaction which is due to or suspected to be the result of a protocol drug must be reported to the Group Chairman or to RTOG Headquarters’ Data Management Staff and to the Study Chairman by telephone within 24 hours of discovery. Known grade 4 hematologic toxicities need not be reported by telephone.

ii. Unknown adverse reactions (≥ grade 2) resulting from commercial drugs prescribed in an RTOG protocol are to be reported to the Group Chairman or RTOG Headquarters’ Data Management, to the Study Chairman and to the IDB within 10 working days of discovery. FDA Form 3500 is to be used in reporting details. All relevant data forms must accompany the RTOG copy of Form 3500.

iii. All neurotoxicities (≥ grade 3) from radiosensitizer or protector drugs are to be reported within 24 hours by phone to RTOG Headquarters and to the Study Chairman.

iv. All relevant data forms must be submitted to RTOG Headquarters within 10 working days on all reactions requiring telephone reporting. A special written report may be required.

Reactions definitely thought not to be treatment related should not be reported, however, a report should be made of applicable effects if there is a reasonable suspicion that the effect is due to protocol treatment.

Investigational Agents

Prompt reporting of adverse reactions in patients treated with investigational agents is mandatory. Adverse reactions from NCI sponsored drugs are reported to:

Investigational Drug Branch (IDB)
P. O. Box 30012
Bethesda, MD 20824
Telephone number available 24 hours
(301) 230-2330 FAX # 301-230-0159

i. Phase I Studies Utilizing Investigational Agents

   - All deaths during therapy with the agent.

   Report by phone within 24 hours to IDB and RTOG Headquarters.
   **A written report to follow within 10 working days.
- All deaths within 30 days of termination of the agent.
- All life threatening (grade 4) events which may be due to agent.
- First occurrence of any toxicity (regardless of grade).

As above
As above
Report by phone within 24 hours to IDB drug monitor and RTOG Headquarters.
**A written report may be required.

ii. **Phase II, III Studies Utilizing Investigational Agents**

- All fatal (grade 5) and life threatening (grade 4) known adverse reactions due to investigational agent.

Report by phone to RTOG Headquarters and the Study Chairman within 24 hours
**A written report must be sent to RTOG within working days with a copy to IDB.
(Grade 4 myelosuppression not reported to IDB)

- All fatal (grade 5) and life threatening (grade 4) unknown adverse reactions resulting from or suspected to be related to investigational agent.

Report by phone to RTOG Headquarters, the Study Chairman and IDB within 24 hours.
**A written report to follow within 10 working days.

- All grade 2, 3 unknown adverse reactions resulting from or suspected to be related to investigational agent.

**Report in writing to RTOG Headquarters and IDB within 10 working days.

** See attached (if applicable to this study) NCI Adverse Drug Reaction Reporting Form
## A. Patient Information
1. Patient Identifier
2. Age at time of event:
   - Date of birth: 
   - In confidence
3. Sex
   - Female
   - Male
4. Weight
   - lbs
   - kgs

## B. Adverse Event or Product Problem
1. [ ] Adverse event and/or [ ] Product problem (e.g., defects/malfunctions)
2. Outcomes attributed to adverse event (check all that apply)
   - Disability
   - Congenital anomaly
   - Life-threatening
   - Hospitalization – Initial or prolonged
   - Other:
3. Date of event
   - (Month/Year)
4. Date of this report
   - (Month/Year)
5. Describe event or problem

## C. Suspect Medication(s)
1. Name (give labeled strength & mfr/labeled, if known)
   - #1
   - #2
2. Dose, frequency & route used
   - #1
   - #2
3. Therapy dates (if unknown, give duration)
   - #1
   - #2
4. Diagnosis for use (indication)
   - #1
   - #2
5. Event abated after use stopped or dose reduced
   - #1
   - #2
6. Lot # (if known)
   - #1
   - #2
7. Exp. date (if known)
   - #1
   - #2
8. Event reappeared after reintroduction
   - #1
   - #2
9. NDC # (for product problems only)
   - 
   - 
10. Concomitant medical products and therapy dates (exclude treatment of event)

## D. Suspect Medical Device
1. Brand name
2. Type of device
3. Manufacturer name & address
4. Operator of device
   - Health professional
   - Lay user/patient
   - Other
   - 
   - 
5. Expiration date
   - (Month/Year)
6. Model #
7. Catalog #
8. Serial #
9. Lot #
10. Other #
11. Device available for evaluation? (Do not send to FDA)
   - Yes
   - No
   - Returned to manufacturer on
   - (Month/Year)
12. Concomitant medical products and therapy dates (exclude treatment of event)

## E. Reporter (see confidentiality section on back)
1. Name, address & phone #
2. Health professional?
   - Yes
   - No
3. Occupation
4. Also reported to
   - Manufacturer
   - User facility
   - Distributor
5. If you do NOT want your identity disclosed to the manufacturer, place an "X" in this box.

---

Submission of a report does not constitute an admission that medical personnel or the product caused or contributed to the event.
ADVICE ABOUT VOLUNTARY REPORTING

Report experiences with:
- medications (drugs or biologics)
- medical devices (including in-vitro diagnostics)
- special nutritional products (dietary supplements, medical foods, infant formulas)
- other products regulated by FDA

Report SERIOUS adverse events. An event is serious when the patient outcome is:
- death
- life-threatening (real risk of dying)
- hospitalization (initial or prolonged)
- disability (significant, persistent or permanent)
- congenital anomaly
- required intervention to prevent permanent impairment or damage

Report even if:
- you’re not certain the product caused the event
- you don’t have all the details

Report product problems – quality, performance or safety concerns such as:
- suspected contamination
- questionable stability
- defective components
- poor packaging or labeling

How to report:
- just fill in the sections that apply to your report
- use section C for all products except medical devices
- attach additional blank pages if needed
- use a separate form for each patient
- report either to FDA or the manufacturer (or both)

Important numbers:
- 1-800-FDA-0178 to FAX report
- 1-800-FDA-7737 to report by modem
- 1-800-FDA-1088 for more information or to report quality problems
- 1-800-822-7967 for a VAERS form for vaccines

If your report involves a serious adverse event with a device and it occurred in a facility outside a doctor’s office, that facility may be legally required to report to FDA and/or the manufacturer. Please notify the person in that facility who would handle such reporting.

Confidentiality: The patient’s identity is held in strict confidence by FDA and protected to the fullest extent of the law. The reporter’s identity may be shared with the manufacturer unless requested otherwise. However, FDA will not disclose the reporter’s identity in response to a request from the public, pursuant to the Freedom of Information Act.

The public reporting burden for this collection of information has been estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send your comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Reports Clearance Officer, PHS
Hubert H. Humphrey Building,
Room 721-B
200 Independence Avenue, S.W.
Washington, DC 20201
ATTN: PRA

and to:
Office of Management and Budget
Paperwork Reduction Project
(0910-0230)
Washington, DC 20503

Please do NOT return this form to either of these addresses.
APPENDIX VI

Dental Evaluations

Dental Care for Irradiated Patients

Goals for a dental care program include:

1. To reduce incidence of bone necrosis.
2. To reduce incidence of irradiation caries.
3. To allow proper fitting of dentures following treatment.

Preirradiation Care and Procedures

The patients may be grouped into four groups in accordance with the problems they present prior to irradiation.

**Group 1**
Includes edentulous patients. They may require surgical removal of any symptomatic cysts, infected retained root tips, or alveolar hyperplasia. These patients require hygiene instruction and precautionary instruction about trauma with premature use of a prosthesis.

**Group 2**
Includes those with poor dental hygiene, including those patients whose teeth are beyond repair by ordinary dental procedure, those with generalized oral sepsis, those with generalized periodontal disease, and those with chronic periapical abscesses or granulomas.

Procedures performed on this group include removal of all remaining teeth prior to irradiation with primary closure and surgical preparation of the alveolar ridges to laterally support a prosthesis. There should be antibiotic coverage during the healing stage and adequate time prior to the start of radiation therapy. These patients need complete hygiene instruction and precautionary instruction about premature use of a prosthesis.

**Group 3**
Includes those in whom dental condition is fair, including those patients whose teeth are restored, ordinary dental procedures, periodontal pockets are less than 3 mm deep, carious lesions are not in proximity to the pulp, and no more than 20 restorable carious lesions are present. X-ray examinations show at least 1/2 of the bone still present around root surfaces. These patients require removal of any teeth which are non-salvageable in accordance with the above and restorations of the remaining teeth as required. The patients are instructed for dental prophylaxis and the patients utilize custom-made fluoride carriers.

**Group 4**
Includes those in whom dental hygiene is good. This includes patients who do not have severe malocclusion in whom few carious lesions are present. Carious lesions are not in close proximity to the pulp and are correctable by conventional methods. These patients require periodontal evaluation and dental prophylaxis training, restorations as needed, no extractions prior to radiation therapy, and fitting for custom carriers.

**Extraction of Teeth**
If extraction of teeth is necessary prior to radiation therapy, the bone must be contoured so that closure at the extraction site is possible. All loose spicules and sharp projections must be removed. The approximation of the gingival tissue must be such that the closure is neither too loose nor too tight. At least 10 days are required for adequate healing prior to initiation of therapy.

**Causative Factors**
The major causative factors appear to be the reduction of the amount of saliva and secondarily, reduced pH in the mouth. This occurs following high dose radiation to the major salivary glands using parallel opposed fields. The decay process usually occurs in the first year following radiation therapy. It tends to occur more quickly in teeth which have a large amount of root cementum exposed to those teeth with large amounts of plaque formation present. Doses of radiation in excess of 20 Gy to salivary tissue place the teeth at risk.
Preventive Program
The rationale behind the use of fluoride treatments is to make the tooth surfaces less susceptible to the decay process. This is accomplished by a combination of increasing fluoride concentration on the tooth surface and by the effect of fluoride on the plaque and flora that are present in the oral cavity. Adequate results are obtained by: 1) cleansing the teeth thoroughly, followed by a good home care dental prophylaxis program, 2) construction of fluoride carriers, custom-made mouth guards which provide local application of fluoride solution to the gingiva and tooth surfaces. Fluoride carriers are made individually with the use of casts. Material used for making a mouth guard is "Sta-Guard" plastic used in conjunction with vacutrole unit produced by Jelrus Technical Products, Corp., both of which are available through local dental supply. This material is molded to the cast impression and allowed to harden. A fluoride solution prepared at the M.D. Anderson Hospital is now available from the Emerson Laboratories, Inc., Dallas, Texas 75221. It has been used to coat the plastic carrier for use in the mouth. The patients are instructed to cleanse their teeth prior to placement of the carrier. It is then worn in place for 5 minutes each day. The patients are instructed to rinse their mouths thoroughly following the use of the carrier. This will be continued for an indefinite period of time. Close follow-up is necessary.

Results
In the 5-1/2 year program at the M.D. Anderson Hospital beginning in 1966, a study of 304 patients shows that the incidence of necrosis of the jaw was reduced to approximately 21% compared to 37% prior to initiation of the study. Groups 3 and 4 patients randomized with and without fluoride treatment showed reduction in radiation carries from 67% to 34% among Group 3 patients, and from 65% to 22% among Group 4 patients.

Failure to Control Decay
Management of failure to control radiation decay includes silver fillings with continued use of fluoride treatments. If the decay process is sufficiently advanced that a filling will no longer stay in place, these teeth are merely smoothed so that there will be no sharp, irritating edges. The mere existence of such a decayed tooth is not necessarily reason for extraction, for it must be remembered that extraction could lead to complications such as bone necrosis.

Pulp exposure resulting from the decay process can usually be handled by use of antibiotics and/or root-canal therapy.

Hypersensitivity of Teeth
Occasionally, a patient will exhibit extreme sensitivity of the teeth secondary to diminished amounts of saliva. This has been shown to be reduced in incidence with the fluoride treatments. Should this problem become manifest, increasing the fluoride treatment to 10 to 15 minutes 3 times a day is recommended.

Infections
Infections occurring in patients under or after radiation therapy are best managed conservatively with good oral hygiene, irrigation and flushing procedures, and systemic antibiotics.

Bone Necrosis
The patients receiving radiation therapy to a high dose to the head and neck region have increased susceptibility to bone necrosis for several reasons including: impairment of normal metabolism, increased susceptibility to infection and severely limited repair process. Bone necrosis occurs most often after post-irradiation surgery or other traumas. Conservative management should be tried first, though in more aggressive lesions a more radical approach may ultimately be necessary.
APPENDIX VIII (4/1/99)

RTOG 97-09

SALAGEN® (pilocarpine)/PLACEBO SHIPMENT FORM

Double-blinded pilocarpine/placebo will be shipped only to institutions who have identified a single individual associated with the investigational drug unit of the institution. This form must be completed and returned to RTOG Headquarters prior to registering any patients on study. Allow adequate processing time (7-10 days) before calling to randomize your first patient.

SHIP TO:

Name: ________________________________

Address: ____________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

Telephone: ________________________________

Fax#: ________________________________

RTOG Institution#: ________________________________

Institution Name: ________________________________

IRB Approval Date: ________________________________

Investigator (PI) Signature ________________________________ Date: __________

Investigator Name (Print) ________________________________

Investigator NCI # ________________________________

Send Completed Form to:

RTOG Headquarters
1101 Market Street
Philadelphia, PA 19107

ATTN: ELAINE PAKURIS
FAX# 215/574-0300

RTOG Headquarters Approval ________________________________ Date: __________